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ABSTRACT (English): 
Alzheimer disease (AD) pathogenesis is the result of an interplay of crossing pathways, as amyloid 
cascade and synaptic failure. It has been shown that Aβ is liberated from the amyloid precursor 
protein (APP) by BACE and γ-secretase activity. Alternatively, APP is cleaved within Aβ domain by 
ADAM10, which prevents Aβ formation. ADAM10 is a synaptic protein and works as sheddase 
towards several neuronal cell adhesion molecules. Therefore, ADAM10 activity can regulate not 
only Aβ generation, but also the synaptic morphology and the degree of functional synaptic 
connectivity. ADAM10 represents a potential pharmacological target for AD because the 
upregulation of its activity limits Aβ formation and affects synaptic function. Since ADAM10 
synaptic localization/activity is controlled by the interactions with different protein partners, we 
aimed at identifying novel protein partners of ADAM10. To this, we performed a yeast two-hybrid 
screening, using ADAM10 C-terminal tail as a bait. We took advantage of several biochemical and 
imaging technique to analyze the role of such interaction.  
The results revealed the cyclase-associated protein 2 (CAP2) as a new ADAM10 binding partner. 
CAP2 is a regulator of actin dynamics and, thereby, of spines morphology, and could be involved 
in the modulation of ADAM10 synaptic localization/activity. Here we confirmed ADAM10/CAP2 
interaction and we identified the domains responsible for the association. Moreover, we defined the 
region of CAP2 involved in actin binding and we analyzed the effect of such domain on ADAM10 
synaptic localization. 
CAP2 can represent the crossing point between different aspects of AD pathogenesis, such as the 
amyloid cascade and actin-dependent spines shaping, thus taking part in a new cellular 
mechanism underlying synaptic dysfunction in AD. 
 
 
 
ABSTRACT (Italian): 
La malattia di Alzheimer (AD) è una malattia neurodegenerativa caratterizzata da un aumento di 
livelli di beta-amiloide (Aβ) e dalla sua deposizione in placche senili. In particolare, la forma 
solubile di Aβ svolge un ruolo importante nelle fasi iniziali di AD, portando a perdita delle sinapsi e 
conseguenti deficit cognitivi. Aβ deriva dalla proteina precursore (APP), che può essere 
sequenzialmente tagliata dalle proteasi BACE1 e γ-secretasi per produrre Aβ. Tuttavia, con un 
meccanismo mutualmente esclusivo rispetto al precedente, APP può essere processato da α-
secretasi (ADAM10) e γ-secretasi; ADAM10 taglia APP all'interno del dominio Aβ, evitando così la 
generazione di Aβ. Inoltre, nei neuroni, ADAM10 è responsabile del taglio proteolitico di diverse 
molecole di adesione, come neuroligin-1, N-caderina, NCAM e Ephrin. Pertanto, in un quadro più 
ampio, ADAM10 ha un importante ruolo nel controllo della morfologia delle spine dendritiche e 
nella plasticità attività-dipendente.  
Dato il ruolo chiave svolto da ADAM10 nella cascata dell’amiloide e nel controllo della morfologia 
delle spine dendritiche, ADAM10 può rappresentare un potenziale bersaglio farmacologico per 
prevenire la degenerazione sinaptica delle prime fasi della patologia di AD. A riguardo, è 
importante sapere che ADAM10 è in grado di agire sui suoi substrati solo quando è inserito 
correttamente nella membrana plasmatica. Di conseguenza il trasporto intracellulare di ADAM10 è 
di rilevante importanza per regolare l’attività dell’enzima stesso. 
Alla luce di queste considerazioni, per identificare possibili proteine partner in grado di regolarne la 
localizzazione, abbiamo eseguito un yeast two-hybrid screening utilizzando la coda C-terminale di 
ADAM10 come esca. I risultati hanno rivelato CAP2 come nuovo partner di ADAM10.  
CAP2 è una proteina poco descritta in letteratura, che svolge un ruolo chiave nella regolazione del 
citoscheletro di actina e nella trasduzione del segnale. Alla luce delle caratteristiche di CAP2, il 
nostro lavoro è stato volto allo studio e caratterizzazione di come questa proteina possa 
influenzare la localizzazione intracellulare di ADAM10 e di conseguenza la sua attività, agendo 
quindi indirettamente non solo sulla produzione di Aβ, ma anche, in generale, sul fisiologico 
rimodellamento delle spine dendritiche. 
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1. INTRODUCTION 
1.1 DENDRITIC SPINES: THE LOCUS OF ALZHEIMER'S 
DISEASE 
1.1.1 ALZHEIMER’S DISEASE 
	
Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder 
characterized by increased levels of amyloid β-peptides (Aβ) and their deposition in 
senile plaques and by the formation of the intracellular Neurofibrillary Tangles (NFTs), 
constituted of hyperphosphorylated Tau protein. ADAM10 prevents Aβ generation 
because it cleaves the Amyloid Precursor Protein (APP) within the Aβ domain. Aβ plays 
a central role in AD pathogenesis. Indeed, the “amyloid hypothesis” was first proposed 
from research conducted in the middle of the 1980s showing that senile plaques found 
in AD brain tissue were composed mainly of a sticky Aβ peptide1. This hypothesis was 
formalised by Hardy and Higgins (1992) who stated that Aβ “precipitates to form amyloid 
and, in turn, causes NFTs and cell death”2. Up to now, most investigators believe that 
the production and cerebral deposition of amyloid plaques composed of the 38 to 42 aa 
Aβ peptide is central to the development of AD3. According to the amyloid hypothesis, 
deposition and accumulation of Aβ in the brain is the primary factor driving AD 
pathogenesis4. In animal models Aβ deposition has also been observed prior to the 
tangle pathology5. Therefore, the basic biochemical formula for Aβ production was 
investigated in minute details to determine the aetiology of the disease. 
The cloning of the gene encoding APP and its localization to chromosome 216,7, 
coupled with the earlier recognition that trisomy 21 (Downs syndrome) leads invariably 
to the neuropathology of AD8, set the stage for the proposal that Aβ accumulation is the 
primary event in AD pathogenesis. In addition, the identification of mutations in the APP 
gene that cause hereditary cerebral haemorrhage with amyloidosis (Dutch type) 
showed that APP mutations could cause Aβ deposition, albeit largely outside the brain 
parenchyma9. Soon, the first genetic mutations causing AD were discovered in the APP 
gene2,10 11. The contemporaneous discovery that Aβ was a normal product of APP 
metabolism throughout life and could be measured in culture medium, cerebrospinal 
fluid, and plasma12-14 allowed scientists to quickly establish the biochemical 
abnormalities caused by APP mutations. The majority of the mutations cluster at or very 
near the sites within APP that are normally cleaved by secretases. In accordance with 
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this, these mutations promote generation of Aβ by favouring proteolytic processing of 
APP by β or γ secretase or increase the relative production of Aβ42 compared to Aβ40 
15. Furthermore, APP mutations internal to the Aβ sequence heighten the self-
aggregation of Aβ into amyloid fibrils16. These exciting developments provided the 
genetic framework for the emerging amyloid hypothesis2,4. In the past years, bolstered 
particularly by the cloning of the γ-secretase  components named Presenilins (PSs) 17,18 
and the demonstration that AD-causing mutations in PS1 and PS2 also enhance the 
processing of APP to form Aβ, the amyloid hypothesis has become the focus of AD 
research. In addition to the cloning of PS1 and PS2 and the discovery that they alter 
APP metabolism19-21  through a direct effect on the γ secretase protease22,23, there have 
been four conceptually important observations that strongly support the amyloid 
hypothesis. First, mutations in the gene encoding the tau protein, the main component 
of NFTs, cause frontotemporal dementia with parkinsonism24-26. This 
neurodegenerative disorder is characterized by severe deposition of tau in NFTs in the 
brain, but no deposition of amyloid. The clear implication is that even the most severe 
consequences of tau alteration - profound NFTs formation leading to fatal 
neurodegeneration - are not sufficient to induce the amyloid plaques characteristic of 
AD. Thus, the NFTs of wild-type tau seen in AD brains are likely to have been deposited 
after changes in Aβ metabolism and initial plaque formation, rather than before4. 
Second, transgenic mice overexpressing both mutant human APP and mutant human 
tau undergo increased formation of tau-positive tangles (as compared with mice 
overexpressing tau alone), whereas the structure and number of their amyloid plaques 
are essentially unaltered27. This finding suggests that altered APP processing occurs 
before tau alterations in the pathogenic cascade of AD, a notion bolstered by the recent 
observation that in mouse hippocampal primary neuronal cultures, Aβ toxicity is tau 
dependent28. Third, crossing APP transgenic mice with ApoE–deficient mice markedly 
reduced cerebral Aβ deposition in the offspring29, providing strong evidence that the 
pathogenic role of genetic variability at the human ApoE locus 30 is very likely to involve 
Aβ metabolism. And fourth, growing evidence indicates that genetic variability in Aβ 
catabolism and clearance may contribute to the risk of late-onset AD 31-34. Taken 
together, these findings are consistent with the notion that cerebral Aβ accumulation is 
the primary mechanism of AD pathogenesis and that the rest of the disease process, 
including tau tangle formation, results from an imbalance between Aβ production and 
Aβ clearance.  
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As the above-described amyloid cascade hypothesis of AD, as initially formulated, 
proposed that the hallmark progressive deposition of insoluble fibrillar Aβ in plaques 
triggered neurodegeneration which, in turn, caused the insidious escalation of 
debilitating symptoms, including progression through the different stages of clinical 
dementia. Support for this proposal came from the discovery that application of fibril 
containing Aβ to cultured neurons was highly toxic in vitro and that intracerebral 
injection of fibril-containing Aβ caused a neurodegeneration-associated disruption of 
performance of cognitive tasks in animals 35,36. However, the relatively poor correlation 
between the severity of clinical dementia at the time of death of patients with AD and 
either the magnitude of fibrillar Aβ load or the extent of neuron loss in the brain provided 
a major challenge for the original amyloid cascade hypothesis37. In fact, many studies 
demonstrated that the best statistical correlation occurs between measures of synaptic 
density and degree of dementia38. Data obtained by electron microscopy39, 
immunocytochemical and biochemical analyses on synaptic marker proteins in AD 
biopsies and autopsies indicate that synaptic loss in the hippocampus and neocortex is 
an early event40 and the major structural correlate to cognitive dysfunction38,41. Not 
NFTs, senile plaques, nor even neuronal loss show such a strong statistical correlation 
with dementia 42,43. Moreover, the decrease in synapse number and density seems 
disproportionate to the loss of neuronal cell bodies38,44, suggesting that pruning of 
synaptic endings may precede the demise of the neuron in the disease process. 
Furthermore, some changes in the brains of AD patients and APP transgenic mice 
suggest that synaptic function is compromised prior to the physical deterioration of 
neuronal structures45-47. This evidence, coupled with the fact that large fibrillar plaques 
present much less Aβ surface area to neuronal membranes than do a multitude of small 
oligomers that can diffuse into synaptic clefts, indicates that such soluble assembly 
forms are better candidates for inducing neuronal and/or synaptic dysfunction than 
plaques, per se. Indeed, human Aβ can exist in diverse assembly states, including 
monomers, dimers, trimers, tetramers, dodecamers, higher-order oligomers and 
protofibrils, as well as mature fibrils, which can form microscopically visible amyloid 
plaques in brain tissues48. Therefore, a new understanding of the amyloid cascade 
hypothesis proposes an alternative mechanism for memory loss based on the impact 
of small, soluble Aβ oligomers4. Indeed, different soluble molecular species that are 
generated at very early stages of the disease could be involved in synaptic failure and 
only at more advanced stages they are deposited in an aggregated form. It has, thus, 
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been suggested that soluble assembly states of Aβ peptides can cause cognitive 
problems by disrupting synaptic function in the absence of significant 
neurodegeneration. Therefore, current research investigates the relative importance of 
these various soluble Aβ assemblies in causing synaptic dysfunction and cognitive 
deficits. 
1.1.2 WHAT IS A DENDRITIC SPINE? 
The synapse is the specialized junction that allows the communication between the 
neurons in the mammalian brain. In particular, the synapses that use glutamate as 
neurotransmitter are defined as excitatory synapses, and they are localized where the 
axon of a neuron contacts the dendrites of another neuronal cell, which receive synaptic 
inputs.  
Most of the excitatory synapses are generally formed at the head of a protrusion, called 
dendritic spine, that is the structure specialized for synaptic transmission. Spines are 
typically small (less than 3 µm in length, from the dendritic attachment to the tip of the 
head), with a head (0.5–1.5 µm diameter) connected by a narrow neck (<0.5 mm 
diameter and 1 μm long) to the dendritic shaft49 . The geometry of the spines is highly 
variable from spine to spine. According the classification of Peters and Kaiserman-
Abramof the spines can be categorized into three essential types: thin, mushroom and 
stubby spines. Thin spines are the most common and have a thin, long neck and a 
small bulbous head. Mushroom spines are those with a large head and are typically 
found in adult brains. Stubby spines are devoid of a neck50,51 , and are particularly 
prominent during early postnatal development52 , although they are still found in the 
adult53. In addition, dendritic filopodia have been observed and are longer that mature 
dentritic spines and normally they haven't a clear head49. Most of the excitatory 
synapses occur on the spine heads where it is possible to detect an electron-dense 
disc-like structure, named PSD (Post Synaptic Density),. The PSD is directly opposed 
to the presynaptic side. The presence of a prominent PSD, that can be revealed by 
Electron Microscopy, is a characteristic of the asymmetric synapses, that are typically 
glutamatergic; in contrast, the inhibitory and symmetric synapses occur mostly on 
dendritic shafts.  
It has been demonstrated, over the years, that the neuronal activity regulates the 
morphology of the spines and, through this modification, controls the synaptic 
transmission and plasticity. Notably, the morphological features of the spines are 
correlated with the synaptic structure: the head volume (and also the total spine volume) 
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is correlated with the PSD area. The PSD is composed of multiple proteins that bind 
each other through specific domain-domain interactions, forming a mesh-like structure 
organized in consecutive layers. The shape and the size of the spines are dependent 
on the developmental stages and on the strength of the synapses54. The most relevant 
feature of this process is the presence in the young brain of the dendritic filopodia. 
Indeed, in the young brain there are many filopodia that partially disappear in the adult 
brain. Although the function of the filopodia is still unknown, it is has been shown that it 
is a very plastic structure that plays a role in the formation of connection among 
neurons, even if it is no clear yet if the spines derive directly from filopodia. Probably 
these structures mediate the process of spines formation even if they are just a transient 
structure. Likewise, the conversion of filopodia to spines is not likely to occur in mature 
neurons, when filopodia are rare and spines can form within minutes to hours, as shown 
in cycling female rats, during the recovery from hibernation as well as in living adult 
mice55 (Fig. 1). 
 
 
1.1.3 SPINES COMPOSITION: THE ORGANELLES 
The soma may not be able to provide enough proteins for the entire cell, and this may 
be due to "structural" limits of the biosynthetic capability of the soma. For this reason, 
the dendrites contain almost all of the cellular machinery necessary to synthesize 
proteins. Moreover, the transport of mRNA designated to the formation of synaptic 
proteins, and their localization and translation, is fundamental for the synaptic 
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Figure	1.	Dendritic	spine	structure 
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composition56.  The polyribosomes are found in the spines, therefore the spines must 
be able to synthesize proteins, even if it is known that the protein synthesis occurs 
mainly in the dendrite shafts57. In particular, since the production of many proteins is 
strictly activity dependent, the protein synthesis is differentially regulated in the spines 
depending on the association of the ribosome with the spines. Several spines contain 
the SER (Smooth Endoplasmic Reticulum), that is a continuous with the RER (Rough 
Endoplasmic Reticulum) of the dendritic tree and that can be extended through the neck 
to the head, sometimes even continuously49. The SER is involved in the intracellular 
trafficking and in the regulation of intracellular Ca2+ stores. The SER, especially in the 
hippocampus, is formed by specific vesicles and tubules, thus creating the “spine 
apparatus”, a stack of SER cisternae and dense plates between them49. Larger spines 
usually contain the “spine apparatus” and the amount of cisternae is correlated with the 
size of the PSD58. 
Protein markers of Golgi membranes, including α-mannosidase II, giantin, and Rab6, 
have been found in the dendrites of some neurons58-60. The dendritic localization of 
these organelles suggests that “satellite” protein secretion can occur at sites far from 
the nucleus. What controls the flow of cargo that passes through several dendritic 
branch points to distal ends of dendrites? Golgi outposts situated at dendritic 
intersections engage in ongoing post-Golgi trafficking61 and are properly positioned to 
regulate the identity or the amount of cargo that is trafficked to each branch. Despite 
the presence of functional Golgi outposts in some hippocampal dendrites, not all 
dendrites possess detectable Golgi. Moreover, even in those dendrites containing Golgi 
outposts, most ER-to-Golgi carriers originating in the dendrite are trafficked all the way 
back to the somatic Golgi62.  Thus, dual modes of early secretory trafficking exist in 
dendrites. In fact, the major mode of ER-to-Golgi trafficking is directed long distances 
to the Golgi apparatus in the soma. This appears to be the exclusive mode of early 
secretory trafficking in those dendrites lacking Golgi outposts.  
Also the mitochondria are present in the dendritic shafts, but not in the spines, and a 
recent study demonstrated that mitochondria mobility in dendrites is controlled by 
synaptic activity. Synaptic stimulation decreased mitochondrial mobility and increased 
the association of mitochondria with dendritic spines63. The high compartmentalization 
of dendrites properties leads to the correct spatial segregation and integration of the 
different pathways required for the structure of the synapse62. 
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1.1.4 SPINES COMPOSITION: FROM RECEPTORS TO SCAFFOLDING 
PROTEINS 
Hundreds of molecules have been described in the spines, and these are involved in 
many biochemical pathways. This molecular complexity is important to make functional 
the synaptic machinery and to create synapses independent from other synapses and 
from the rest of the neuron49 (Yuste, 2010). 
Glutamate receptors  
Glutamate is the most important excitatory neurotransmitter in the brain. It is released 
from vesicles from pre-synaptic sites and interacts with its receptors on the post-
synaptic site. The glutamate receptors are: ionotropic receptors (iGluR) and G-protein 
coupled receptors (mGluR). The first type of receptor give rise to fast postsynaptic 
response, while the metabotropic receptor produces slower postsynaptic effects. 
Several types of iGluRs have been identified: AMPARs (receptors activated by α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate), NMDARs (receptors activated by 
N-methyl-D-aspartate), and kainate receptors (receptors activated by kainic acid)64.  
NMDARs are heteromeric assembly of different subunits that form a non-selective 
cation channel and allow the entry of Ca2+ in addition to monovalent cations, as Na+ 
and K+. NMDARs are activated only when presynaptic glutamate release coincides with 
sufficient post-synaptic depolarization. Extracellular Mg2+ exerts a voltage-dependent 
block of the opened ion channel65 and so it is necessary the relieve of the Mg2+ block 
of the ion channel66. Moreover, not only the glutamate, but also the binding of glycine 
appears to be necessary for receptor activation67. At hyperpolarized membrane 
potentials, more negative than -70 mV, the concentration of Mg2+ in the extracellular 
fluid is sufficient to virtually abolish ion flux through NMDARs channels even in the 
presence of glutamate and glycine. A positive change in transmembrane potential will 
increase the probability of the exit of Mg2+. NMDARs are composed of multiple subunits 
(GluN1, GluN2A-D, GluN3) that assemble in heteropentameric or heterotetrameric 
structures. These structures exhibit distinct properties depending on the subunit 
composition. The various isoforms of NR2 subunits contain the glutamate-binding site68 
while glycine-binding site appears to be located on the NR1 subunit. NR1 is essential 
for NMDAR function and eight receptor variants can be generated by alternative 
splicing69. The GluN2A subunit confers a lower affinity for glutamate, distinct faster 
kinetics, greater channel open probability and more prominent Ca2+-dependent 
desensitization compared to GluN2B. The GluN2D and GluN2C subunits are 
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characterized by low conductance openings and reduced sensitivity to Mg2+ block.  
NR3-containing receptors are more predominant in a narrow time window during 
development. The GluN3 containing receptors are considered a distinct class of 
nonconventional NMDARs since GluN3 shows limited sequence homology to GluN1 
and GluN2 and since it confers unique properties to the channel. NMDARs have been 
shown to contain consensus sequences for phosphorylation by protein kinases70. 
CaMKII (Calcium/calmodulin-dependent protein kinase II) can associate to GluN1, 
GluN2A and GluN2B which can be phosphorylated also by other kinases as PKC 
(Protein Kinase C) or PKA (Protein Kinase A). In the brain, between 10 and 70% of NR1 
and NR2 subunits seem to be phosphorylated by PKA or PKC71 thus increasing the 
heterogeneity of NMDARs. 
AMPARs are heterotetramers composed of the subunits GluA1-4 72. They are activated 
by glutamate and antagonized by 6-ciano-7-nitroquinoxaline-2,3-dione (CNQX) and 
2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX). These receptors are the 
major mediator of fast glutamatergic excitatory synaptic transmission in the central 
nervous system (CNS). AMPARs can assume different role depending on their 
composition: AMPARs containing GluA2 subunits show lower permeability to Ca2+, 
while receptors containing GluA1, GluA3 and GluA4 are permeable to Ca2+ 73. The 
differences among the subunits are due to an alternative splicing74. All the subunits of 
AMPARs have phosphorylation sites on their C-terminal tail that regulate their function 
and that seem to be involved in the regulation of synaptic plasticity. GluA1 is one of the 
most abundantly expressed subunit of AMPARs in hippocampal and neocortical 
neurons75. Most of the phosphorylation on GluR1 occurs on serine and threonine76, and 
tyrosine residues77. Ser831 and Ser845 are involved in the expression of LTP and 
LTD78. PKC and CaMKII mediate the phosphorylation on GluA1-Ser83179, while GluA1-
Ser845 is phosphorylated by protein kinase A (PKA). This phosphorylation can enhance 
currents through AMPARs80. GluR2 is a key subunit which renders AMPARs channel 
impermeable to Ca2+ and confers specific biophysical properties81. There are several 
serine phosphorylation sites (Ser863 and Ser880) on the C-terminal tail of GluA2. The 
kinase that act on the GluA2 is the PKC82. GRIP family stabilize AMPARs at the synaptic 
side (Dong et al., 1997) and as intracellular pools83. The phosphorylation of Ser880 give 
the AMPARs the capability to bind PICK-1 (Protein Interacting with C Kinase-1), that 
either promotes the endocytosis of the receptor84 or allows its trafficking to the plasma 
membrane83. GluA3 and GluA4 are not highly expressed in the adult forebrain 
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structures compared to GluA1 and GluA2 subunits85. Expression of GluA4 in the 
hippocampus is limited during early post-natal period development and GluA4 can be 
inserted into synapses by spontaneous activity86. 
Scaffolding proteins: the MAGUK family  
The Membrane Associated Guanylate Kinase (MAGUK) family is a super family of multi-
domain proteins characterised by the presence of a shared set of structural domains. 
The MAGUK family includes the post-synaptic density 95 (PSD-95), chapsyn-110, 
synapse-associated protein 102 (SAP-102), and SAP-97. They are key protein in 
governing the localisation of the glutamate receptors at synapse and their function. 
According to their function, these proteins are present in the PSD, since the 
synaptogenesis (Boeckers et al., 1999). Their multi-domain structure is fundamental for 
their correct localisation and activity. They contain three PDZ (PSD-95/DLG/ZO1) 
domains, a Src homology 3 (SH3) region and a Guanylate Kinase (GK)-like sequence. 
They are all localized in the CNS87, but each member is distributed differently in brain 
cell compartments. PSD-95 and PSD-93 are highly enriched in the PSD 88, where they 
interact with the cytoplasmic tail of NMDA receptor subunits, while SAP97 and SAP102 
have been found in dendrites and axons and are abundant in the cytoplasm as well as 
at synapses and are involved in the trafficking of NMDARs and AMPARs respectively, 
SAP102 can associate with the exocytosis and regulate the delivery of NMDARs to the 
surface of the plasma membrane. Since these properties are related to the capability of 
MAGUK proteins to interact with other PSD components, it is important to understand 
the structural characteristics of their domains. PDZ domain scaffolds have been shown 
by genetic, electrophysiological and morphological studies to be essential for controlling 
the structure, strength and plasticity of synapses. SH3 modules regulates protein–
protein interactions. SH3 ligands are composed of seven residues and contain PXXP 
sequences. The GK module, typical domain of the enzyme that catalyses the 
conversion of GMP to GDP, mediates protein–protein interactions independently of its 
predicted enzymatic activity89. Indeed, the MAGUK proteins are predicted to bind 
neither GMP nor ATP and are, therefore, assumed to be enzymatically inactive. 
 
Adhesion molecules 
The adhesion molecules are important for the formation and the development of the 
synapses, since they are involved in the formation of the dendritic spines55. Indeed, 
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they mediate the connection between an axon and a dendrite. However, they are 
expressed at mature synapse regulating plasticity and consequently contributing to a 
variety of cognitive functions, including learning and memory.  For that reason, they are 
involved in the continual synapse remodelling. CAMs affect spine structural changes by 
influencing the actin cytoskeleton through molecular links or by engaging singling 
cascades. They can link in a stable way the presynaptic side to the postsynaptic side, 
giving the structure and stability to the synapse. They can nevertheless modulate the 
remodelling through their proteolytic cleavage disrupting the connection with the 
presynaptic side. Moreover, the CAM cleavage can also affect a variety of 
neurotransmitter receptor-CAM interactions to strongly influence the degree of 
functional synaptic connectivity. Different adhesion molecules, among which N-
cadherin, Ephrins, Integrin, the adhesion molecules of neuronal cells (NCAM, neural 
cell adhesion molecule), Densin-180 and Neuroligin-149, are localised in spines. The 
adhesion molecules are bound to the actin cytoskeleton. The N-cadherin interact with 
the actin filament thought β-catenin and α-catenin 90. The Integrin91 and Densin-180 92 
are bound to the alpha-actinin while the Neuroligin-1 is bound to the actin filaments 
through PSD-95. In particular, the CAM capability to link these additional associated 
proteins results in a larger multi-molecular complexes. For example, at the postsynaptic 
side, PSD-95, a MAGUK scaffold protein, binds to neuroligins, NMDA receptors, and 
also TARPs that in turn link to AMPA receptors. 
The CAMs are classified in homophilic or heterofilic, the homophilic CAM link interact 
with a partners across the two side of the membrane belonging to the same family, 
while the homofililic interaction occurs between CAMs belonging to different families. 
For example, the cadherin superfamily members belong to the homophilic class 93. 
Among them, N-cadherin, is expressed at both excitatory and inhibitory synapses 
during early development but later becomes preferentially enriched at excitatory 
synapses94. This could reflect distinct roles played by N-cadherin first in synapse 
formation and subsequently in mature excitatory synapse function. The N-cadherin, 
through a morphological change in its conformation, is necessary for the activity-
dependent enlargement of the spine. The N-cadherin principal role is the maintenance 
of the dendritic spine. Indeed, N-cadherin can modulate the spine morphology 
regulating the availability of the glutamate receptors95. N-cadherin is important for the 
maintain of the synaptic levels of AMPARs, because the N terminal domain of the GluA2 
subunits of AMPARs can interact with the synaptic N-cadherin 96,97. 
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1.2 THE SPINOSKELETON: ACTIN IN ACTION IN THE 
SPINES 
Actin is one of the most enriched protein in the synapses. Half of it is present in its 
glomerular form (G-actin) and half of it in the filamentous part (F-actin). The actin 
cytoskeleton formation process in the spine is highly dynamic and strictly regulated. The 
G-actin polymerizes to F-actin using an ATP-dependent hydrolysis that allows the 
formation of the filamentous actin. The filamentous actin is a polarized structure. It is 
possible to recognise a fast growing site on that structure (the barbed end, the side 
where the monomers are added) and the side where the actin depolymerize (the 
pointed end)98. 
The the actin bound to the ADP (ADP-actin) has the same affinity for both sides of the 
actin filament, while the monomer of actin bound to the ATP (ATP-actin) can bind the 
barbed-end because of the hydrolysis of ATP to ADP.  
The cycle of polymerization and depolymerization of actin is influenced by the G-actin 
concentration inside the cell. When G-actin concentration is higher than 0,1 µM, an 
increase in polymerization is observed until G-actin concentration goes back to 0,1µM, 
called “critical concentration”. In the physiological conditions the concentration of the G-
actin is between 50-200 µM. This high actin concentration is permitted by the presence 
of actin binding proteins that maintains the “critical concentration”. Indeed, a lot of 
proteins are able to sequester and bind G-actin, such as profilin, timosin β 4, the WASp 
(Wiskott-Aldrich Syndrome proteins) and the CAPs (Cyclase Associated Proteins) 99-
102. Anyway, the majority of the ABP (Actin Binding Proteins) are proteins necessary for 
the regulation of the actin filaments, such as the capping protein, the tropomodulin, the 
gelsolin and Cap Z 103,104. They bind the terminal part of F-actin (barbed-end) preventing 
the binding of the G-actin. Another class of F-actin binding proteins are responsible for 
the severing, since they break the actin filament creating new barbed ends for the 
polymerization of actin. 
The spinoskeleton represents the cytoskeleton of the spine. The principal component 
of the spinoskeleton is the F-actin that occupies the total volume underneath the PSD 
in the spine105. The actin gives to the spine stability and structure, influencing the shape 
and motility. The actin can assume different shapes: (1) the branched actin, that is 
mainly present in the distal part of the spine, and (2) the linear part, that is more equally 
distributed106. 
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filaments in the head of the spine are highly dynamic, giving rise to a phenomena called 
actin treadmilling 107,108, that occurs when one end of an actin filament grows in length 
(at the barbed end) while at the other end (the pointed end) there is a constant removal 
of the actin subunits. 
The spinoskeleton is composed of two main parts: the core and the shell. The shell is 
the actin present in the terminal part of the spine that is highly dynamic (turnover rate: 
10 sec). The other part is the core that represents the actin localized in the central part 
of the spine, where the turnover is slower, around 10 minutes105. 
It is clear that the core represents the structural part of the spine and is more stable. 
While the dynamic capability of the actin in the shell part can allow the elongation of 
actin filaments and can permit the nucleation of the new filaments relevant for the 
structural growth of the spine 105. 
 
1.2.1 ACTIN BINDING PROTEINS  
The ABPs regulate the physiology of actin giving to the actin the characteristic 
dynamism and stability.  The most important and investigated in dendritic spines are: 
 
Arp2/3 (actin-related protein 3) 
It’s a complex made of different subunits, among which Arp2, Arp3, ARPC1, ARPC2, 
ARPC3, ARPC4 and ARPC5. The Arp2/3 is the principal actin filaments nucleator109. It 
can bind the filamentous actin to both sides and allows the insertion and creation of an 
additional filament 110. It is enriched in the PSD and its downregulation results in an 
impairment in the spine head formation98,111. It is activated by several proteins, such as 
Cortactin, Abi2, WAVE-1 (WASp-family verprolin homology protein-1), N-WASP (neural 
Wiskott-Aldrich syndrome protein) and Abp1. The deletion of such proteins is related to 
memory deficits 112-115 . 
 
Profilin I and Profilin II 
This class of protein is fundamental for the actin polymerization. They are responsible 
for the ADP to ATP nucleotide exchange on actin. These proteins catalyse actin 
polymerization in a concentration-dependent manner, it serves as a catalyst at lower 
concentrations and as inhibitor at higher levels116 . The profilin II is the principal isoform 
in the mammalian brain109, even if profilin I is also expressed 117. 
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ADF/cofilin 
These proteins can promote the actin turnover (Fig. 2). In particular, they can bind G-
actin and F-actin in a stoichiometric ratio 1:1, leading to a depolymerisation of the actin 
filaments from the pointed-end and, thereby, promoting the depolymerisation, but they 
can also create new barbed-ends. The cofilin, which exist in two isoforms, cofilin I and 
cofilin II, belongs to a highly conserved protein family, as the ADF (or destrin)118. The 
role of this complex is fundamental for continuous treadmilling of actin. In fact, since the 
actin monomers are fundamental for a fast reorganisation of the actin cytoskeleton, the 
complex ADF/cofilin promotes the depolymerisation of actin and creates a new pool of 
G-actin monomers available for other filaments formation 119. The result of this activity 
is the correct maintenance for the morphology of the spine111. Indeed, the LIMK1 
activation (LIM kinase 1), that inhibits the ADF/cofilin activity, leads to an altered 
morphology of the spine function120.  
 
 
 
Eps8 
Eps8 (epidermal growth factor receptor pathway substrate 8) is a capping protein. 
Capping proteins (CP) regulate actin polymerization by binding the barbed end of an 
actin filament, which blocks addition and loss of actin subunits121. The capping proteins 
are distributed in dendritic spine and their function is relevant to inhibit the filopodia 
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(Kovar et al., 2000; Kovar et al., 2001; Perelroizen et al., 1996)
and CAP is the only known nucleotide exchanger for G-actin in
plants (Chaudhry et al., 2007). However, unlike profilin, which
preferentially binds to ATP–G-actin (Pantaloni and Carlier,
1993), CAP binds to ADP–G-actin with a relatively high affinity
and effectively competes with ADF/cofilin for binding to ADP–
G-actin (Mattila et al., 2004; Moriyama and Yahara, 2002). Yeast
profilin has a much weaker nucleotide-exchange activity than
mammalian profilin (Eads et al., 1998; Wen et al., 2008) and fails
to enhance nucleotide exchange when ADF/cofilin is bound to
ADP–G-actin (Chaudhry et al., 2010). Thus, a sequential
processing mechanism of actin monomers by CAP (for ADP/
ATP exchange) and profilin (for the incorporation of ATP–G-
actin to actin barbed-ends) has been proposed in yeast (Mattila
et al., 2004). In addition, profilin binds to P1 of Srv2/CAP and
collaborates in polarized actin localization in yeast (Bertling et al.,
2007) (Fig. 3). However, the functional relationship between
CAP and profilin is not well understood in other organisms. For
instance, mammalian profilin enhances the nucleotide exchange
of G-actin to much faster rates than yeast profilin (Wen et al.,
2008), but it is unclear whether profilin and CAP function in a
redundant or hierarchical manner to regulate actin turnover in
mammalian cells.
In human CAP1 and yeast Srv2/CAP, HFD in the N-terminal
half of CAP binds to the ADF/cofilin-actin complex (Fig. 3) and
augments the ADF/cofilin-mediated turnover of actin filaments
(Moriyama and Yahara, 2002; Quintero-Monzon et al., 2009).
These results were originally interpreted as evidence for an active
involvement of HFD in the dissociation of the ADF/cofilin-actin
complex. However, a recent study shows that HFD is not required
for the recycling of ADF/cofilin and G-actin but, instead, has a
separate function in actin filament severing (Chaudhry et al.,
2013), which is discussed below.
The sites necessary for monomer sequestering and nucleotide
exchange activities of CAP reside in its C-terminal half that
contains WH2 and CARP (Fig. 1A). The C-terminal half of CAP
can bind to one molecule of G-actin (Freeman et al., 1995), and
WH2 and CARP bind independently to G-actin (Chaudhry et al.,
2010; Makkonen et al., 2013; Mattila et al., 2004; Peche et al.,
2013), suggesting that they separately contact G-actin. An N-
terminal part of WH2 from other proteins, such as WASP, was
found to bind to G-actin at a cleft between its subdomains 1 and 3
(Dominguez, 2007), and WH2 of CAP might bind to G-actin in a
similar manner. Although a CARP-binding site on G-actin has
not been determined, mutations in its subdomains 2 and 4 –
which are the candidate sites for CARP binding – disrupt its
interaction with Srv2/CAP in yeast (Amberg et al., 1995).
Although the CARP domain is sufficient to promote the
nucleotide exchange of ADP–G-actin (Makkonen et al., 2013),
WH2 is necessary to facilitate nucleotide exchange when ADF/
cofilin is bound to ADP–G-actin (Chaudhry et al., 2010; Nomura
and Ono, 2013). Since ADF/cofilin and WH2 share the same
binding site on G-actin (Dominguez and Holmes, 2011), WH2
might be needed for CAP to be able to compete with ADF/cofilin
for G-actin binding. Nonetheless, the structural basis for the
acceleration of the nucleotide exchange of G-actin by CAP is
largely unknown.
Effects of CAP on F-actin – enhancement of filament
severing
CAP also directly interacts with actin filaments and enhances
filament disassembly (Moriyama and Yahara, 2002). Recent
microscopic observations have clearly demonstrated that CAP
induces the severing of actin filaments (Fig. 3) (Chaudhry et al.,
2013; Normoyle and Brieher, 2012). Mammalian CAP1 alone
can sever actin filaments at an acidic pH but not at neutral pH
(Normoyle and Brieher, 2012), whereas mammalian and avian
ADF/cofilins efficiently sever actin filaments at basic pH but not
at neutral and acidic pHs (Hawkins et al., 1993; Hayden et al.,
1993; Yonezawa et al., 1985). However, when CAP1 and ADF/
cofilin are combined, they promote severing of actin filaments
within a wide pH range (Normoyle and Brieher, 2012). Thus,
either CAP1 or ADF/cofilin alone might function as a pH-
dependent F-actin disassembly factor, but CAP1 and ADF/cofilin
might act together as pH-independent F-actin disassembly
factors. Yeast Srv2/CAP also promotes the severing of ADF/
cofilin-bound actin filaments and this activity is mediated by the
N-terminal half of Srv2/CAP that contains the coiled-coil region
and the HFD (Chaudhry et al., 2013). This activity of CAP
resembles that of actin-interacting protein 1 (AIP1), which
promotes the severing and disassembly of ADF/cofilin-bound
actin filaments (Ono, 2003) (Fig. 3). Indeed, a genetic study in
yeast suggests redundant functions of the N-terminal half of Srv2/
CAP and AIP1 (Chaudhry et al., 2013). However, the mechanism
of how actin filaments are severed by the HFD of CAP still
remains unclear. Functionally important surface residues in HFD
of yeast Srv2/CAP have been mapped to the surface of the HDF
protein, opposite to the location of its N- and C-termini.
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Fig. 3. Regulation of actin filament dynamics by CAP, ADF/cofilin,
profilin and AIP1. CAP competes with ADF/cofilin for binding to G-actin
(right) and promotes its nucleotide exchange (top). CAP also promotes
severing of ADF/cofilin-bound actin filaments (bottom). These activities are
similar to those exerted by profilin and AIP1. ADF/cofilin cooperatively binds
to actin filaments and severs them at the boundary between ADF/cofilin-
bound and the bare segments (Elam et al., 2013). Note that the molecular
organization of the CAP oligomer is hypothetical. Also note that CAP binds
to actin monomers in an oligomeric form but, for simplicity, only a
monomeric CAP is shown as a G-actin-bound form.
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Figure	2.	Actin	treadmilling	
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formation122. The actin-capping proteins control the organization of filopodia. They can 
cap the newly branched filaments created by the Arp2/3 complex, thus controlling the 
elongation of the filopodia and the concentration of the free G-actin monomers123-125. 
 
Myosin II and myosin IV 
These proteins are complexes constituted by four light and two heavy chains and they 
regulate the actin filaments contraction55. The myosin II (in particular the isoform 
MyH10) is localized in the synapses and can regulate the morphology of the dendritic 
spines and the synaptic strength55. Also the isoform MyH7B can cooperate with MyH10 
to control the correct morphology of the spine109. The myosin IV (the isoform Myo6) is 
involved in the internalisation of the AMPA receptor and the Myo6 KO shows a decrease 
in the number of synapses.  
 
Drebrin A 
Drebrin can bind the F-actin and promotes the polymerisation of actin126 (Hayashi and 
Shirao, 1999). It is localized in postsynaptic terminals in adult brain and a decrease in 
drebrin levels has been shown in AD patients127. However, it is well known that is 
involved in spine formation in the early stage of the development regulating the F-actin 
polymerisation. 
 
Rho family of GTPases 
They are Ras protein. There are different components of the family, among which RhoA 
(Ras homolog gene family, member A), Rac1 (Ras-related C3 botulinum toxin substrate 
1) and Cdc42 (Cell division control protein 42 homolog). All the members of this family 
have been studied in neuronal cells since they are involved in the neuronal 
morphogenesis. In the dendritic spine the Rho activation is fundamental for the cofilin 
phosphorylation and therefore for the actin stabilisation of the spine109. While the Rac1 
and Cdc42 activation leads to an enlargement of the head spine111 115, promoting the 
formation of Arp2/3 complex. 
 
1.2.2 CAP (Cyclase-Associated Protein) 
CAP (Cyclase-Associated Protein), originally isolated from the Saccharomyces 
Cerevisiae, are components of the complex responsible for the Ras–cAMP signalling 
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activating the adenylate cyclase (AC) and are involved in the regulation of the 
cytoskeletal structure. Indeed, the yeast lacking of CAP is unable to grow on an 
enriched medium, are not resistant to the temperature in a minimal media and, 
moreover, present changes in cell morphology such as a shape rounder and larger than 
normal cells. Therefore, it has to be assumed a fundamental role of CAP in the cell 
growth. It should also be considered that not all the CAP physically interact with AC or 
regulate its function. For example the CAP proteins of Schizosaccaromyces pombe, 
which are structurally and functionally related to CAP of S. cerevisiae128, are not closely 
involved in the RAS signalling. This suggests that CAP are bifunctional proteins, able 
to interact with the pathway of AC activation, but also directly with actin. In addition, the 
activities of Srv2/CAP in cell growth and cytoskeletal organization are conserved also 
in CAP homologues129. 
 
1.2.2.1 CAP STRUCTURE 
CAPs are multidomain proteins of 450-550 amino acids and vertebrates have two CAP 
homolog forms, CAP1 and CAP2130. CAP is a predominantly hydrophilic protein, made 
up of α- helix, and of a β-sheets region located in the C-terminal region. 
The most important structural and functional domains of the CAP protein of S. 
cerevisiae are:  
1-the N-terminal domain, which interacts with AC and is required to activate the RAS 
protein; 
2- the C-terminal domain, which is involved in cytoskeletal rearrangement131,132. Indeed, 
the deletion of the C-terminal domain leads to the expression of abnormal phenotypes: 
slow growth, altered cell morphology and actin dynamics.  
3- the central domain rich in proline, between the N-terminal domains and C-terminal, 
responsible for the interactions with proteins containing SH3 domains. 
N-terminal domain 
This region contains tandem repetitions of a heptad motif alphaXXalphaXXX (where 
alpha represents a hydrophobic amino acid and X represents any amino acid), 
suggesting a coiled-coil structure133. The alpha-helical coiled coil is one of the principal 
subunit oligomerization motifs in proteins134 and, in the yeast, is a highly conserved 
motif sufficient for the interaction with AC. 
In yeast, this highly conserved motif interacts with AC. However, the amino-terminal 
domain of human CAP does not have the same function. Therefore, this structurally 
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conserved RLEXAXXRLE motif (where X represents non-conserved amino acid) has 
diverged functionally during evolution but may still be critical for CAP function in all 
organisms. Indeed, the coiled coil regions in other signalling proteins could interact with 
this motif in higher eukaryotes 129.  
The structure of the N-terminal domain of CAP (residues 51-226) was solved by X-ray 
diffraction135 showing that most of the N-terminal region is composed of a stable bundle 
of six antiparallel α-helices that are termed helical folded domain (HFD). The HFD binds 
to the ADF/cofilin-G-actin complex136,137 and also interacts with ADF/cofilin to promote 
the severing of actin filaments138. 
 
Central domain 
There are two proline rich regions in the central region of CAP: P1 and P2. P1 is highly 
conserved among different species, while P2 is less conserved.  
Several of the CAP partners bind selectively P1 or P2. For example, the SH3 domain 
of Abl tyrosine kinase binds P1 of human CAP1, while Abp1 yeast protein binds to the 
P2 srv2 / CAP139,140. 
Recent experiments141 with Drosophila CAP have detected a region just downstream 
from the SH3 binding domain that shows similarity to the verprolin homology domain 
(LKKAET), called WASP homology domain, found in a variety of actin binding proteins 
(e.g., thymosin, fimbrin, actinin and members of the WASp family). The WASp 
homology domain of CAP binds to G-actin without a clear preference between ATP-
actin or ADP-actin, but it has a crucial role in actin nucleotide exchange. 
 
C-terminal domain 
Regarding the C-terminal domain, it has been demonstrated that the deletion of the last 
27 aminoacids abolishes the binding of CAP to actin in S. cerevisiae142 and humans143. 
Within this region there is a 7 a.a. stretch constituting the site E (X) 3PEQ: residues E, 
P and Q are present in all the analysed CAP proteins. 
The C-terminal portion of CAP is mainly made up of β-sheets144. The 35 amino acids 
sequence in the C-terminal domain contains a dimerization motif. 
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1.2.2.2 ROLE OF CAP IN ACTIN DYNAMIC 
CAP has a critical role in the RAS signalling pathway, but several studies suggest that 
this signalling function is related to a limited number of organisms, while its capability 
of maintaining the cytoskeleton structure appears to be conserved among 
eukaryotes129. 
The morphological abnormalities in cells lacking of CAP are associated with the lack of 
proper distribution of actin, the loss of normal bundles of actin and the formation of 
abnormal bundles132. In addition, the expression of a heterologous CAP protein in yeast 
cells lacking of CAP, can recover the phenotype linked to actin, but not the phenotype 
associated to RAS, suggesting that the actin regulation is the evolutionarily conserved 
role128. Similar genetic studies have shown that the regulatory function of the events 
related to actin has been preserved in the CAPs of Lentinus edodes (shiitake 
mushrooms) 145, rat 143 and human146. 
 
1.2.2.3 CAP AND G-ACTIN 
Early biochemical studies demonstrated that CAP sequesters actin monomers 
preventing the nucleation of actin and the filament elongation147. However, recent 
studies have revealed that CAPs play more active roles in promoting the dynamics of 
actin filaments. 
CAP binds to G-actin in a molar ratio 1: 1, and inhibits the spontaneous polymerization 
of G-actin in the F-actin. This activity has been demonstrated in vitro for the CAPs of S. 
cerevisiae147, Dictyostelium148, C. elegans (CAS-1 and DAC-2)149, pork (ASP-56 / 
CAP1) and human (CAP2)150. 
The effect of CAP on actin is controversial. Freeman and collaborators147 show that 
yeast CAP inhibits the incorporation of G-actin at both ends of the actin filament (to the 
pointed-end and to the barbed-end), while Mattila and colleagues151 report that CAP 
selectively inhibits the incorporation of G-actin to the barbed-end. This discrepancy 
could be due to different ratios of CAP and G-actin used in these studies, since it was 
shown that human CAP1 accelerates the addition of G-actin to the barbed-end when it 
is present in sub-stoichiometric amounts respect to the G-actin, but inhibits the addition 
of the monomer when they are used in stoichiometric amounts136. 
At the actin steady state, when CAP is present in an equimolar concentration to G-actin, 
CAP sequesters G-actin 152. In yeast, CAP locates in actin patches140, while in 
Dictyostelium and mammalian cells is localized in the cell periphery 148,153; therefore, in 
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these areas, the concentration of CAP may be high enough to sequester actin 
monomers.  
CAP also increases the rate of nucleotides exchange on actin, and this can represent 
the most important effect on the actin polymerization. During the treadmilling of actin, 
exchange of actin-bound nucleotide occurs primarily at G-actin, whereas hydrolysis of 
ATP into ADP occurs primarily at F-actin. The newly depolymerized actin monomers 
are predominantly bound to ADP. When free ATP is present, ADP–G-actin can 
‘recharge’ itself by rapidly exchanging ADP for ATP and, thus, maintaining the 
treadmilling cycle. However, when no free ATP is available, ADP–G-actin cannot 
recharge itself, thus preventing the treadmillingcycle154-158. However, different G-actin 
binding proteins, including thymosin β4 159 and ADF / cofilin are able to inhibit this 
nucleotides exchange and, therefore, to prevent the process of "actin-recharging". 
CAP is able to promote the exchange of the nucleotide bound to the G-actin160,161 and 
so to increase the turnover of actin in the presence of thymosin β4162,  ADF / cofilin or 
profilin163. 
However, unlike the profilin99, CAP binds to the ADP-G-actin with relatively high affinity 
and competes for it with ADF / cofilin151. 
In human CAP1 and yeast CAP, the HFD domain binds to ADF cofilin-actin complex, 
and increases the actin turnover mediated by ADF/cofilin 136,137. These results were 
originally interpreted as evidence of an active involvement of the HFD domain in the 
dissociation of the complex ADF/cofilin-actin. However, a recent study shows that the 
HFD domain is not required for the recovery of ADF / cofilin and G-actin but, instead, 
has a severing function on the polymerized actin filament. 
The sites necessary for monomer sequestering and nucleotide exchange activities of 
CAP reside in its C-terminal. The C-terminal half of CAP can bind to one molecule of 
G-actin147, and WH2 and CARP bind independently to G-actin150,151,164. 
Although the C-terminal half of CAP is sufficient to promote the nucleotide exchange of 
ADP–G-actin, WH2 is necessary to facilitate nucleotide exchange when ADF/ cofilin is 
bound to ADP–G-actin165. 
Since ADF / cofilin and WH2 share the same binding site for the G-actin (Dominguez 
and Holmes, 2011), WH2 might be necessary to CAP to be able to compete with 
ADF/cofilin. 
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1.2.2.4 CAP AND F-ACTIN 
CAP also interacts directly with the filaments of F-actin and promotes depolymerization 
of the filament. Recent observations have clearly shown that CAP induces cleavage of 
actin filaments166. For example mammalian CAP1 is able, alone, to sever actin filaments 
at acidic pH condition, but not at neutral pH, while the ADF / cofilin of mammal is able 
to “cut” actin filaments in basic pH, but not at neutral and acidic pH. However, when 
CAP1 and ADF / cofilin are combined, they promote the breakdown of actin filaments 
within a wide pH range.  
In addition, yeast CAP promotes the severing of actin linked to ADF / cofilin, and this 
activity is mediated by the N-terminal portion of CAP containing the coiled-coil region 
and the HFD domain138. However, the mechanism by which the actin filaments are 
cleaved from CAP HFD domain remains unclear. 
1.2.2.5 CAP2 (Cyclase-Associated Protein 2) 
Higher eukaryotes have two homologs of CAP, CAP1 and CAP2, which share high 
homology. CAP1 is equally distributed in the organs of the mouse and is highly 
abundant, while CAP2 is expressed only in the skeletal muscle, heart, testis and brain. 
The N-terminal part of CAP2 is conserved through all the species, in particular the 
sequence LxxRLE/DxxxxRLE.  
The best characterisation of CAP2 in mammalian cells, up to now, is made by Peche 
and colleagues, that generate a CAP2gt/gt knockout mice. This model show a particular 
phenotype: 
1-Mutant mice showed a decrease in body weight and had a decreased percentage of 
survival (they survive not over 70 days in comparison to WT animals). Further, they 
developed dilated cardiomyopathy (DCM) associated with drastic reduction in basal 
heart rate and prolongations in atrial and ventricular conduction times. A further finding 
is that mortality due to DCM and atrial dilation is more evident in male than female 
animals. The authors demonstrated that this is due to the dishevelment of sarcomere. 
The lack of CAP2 leads to the loss of the G-sequestering capability of the protein and 
so to the filament-fragmenting activity. They demonstrated that CAP2 is present in the 
Z-line-banding pattern of the sarcomeres and regulates filament formation150. 
2-Kosmas and colleagues showed that the keratinocytes of mutant mice showed 
reduced velocity and a delay in scratch closure. They showed that CAP2 in murine and 
human skin is present in the nucleus, in the cytosol and in the cell periphery; moreover, 
they reported that interestingly, in human wounds, CAP2 was also expressed in 
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hyperproliferative epidermis and at the migrating tongue. CAP2gt/gt fibroblasts develop 
abnormal protrusions and more focal adhesions and show reduced velocity. The 
authors proposed a model according to which, the CAP2 knockout cells motility is 
affected by stabilization of focal adhesions and by disruption of cell polarity, since the 
depletion of CAP2 leads to an increase in focal adhesion in resting and in migrating 
cells167. 
3-Kumar and colleagues showed that CAP2 is highly express in different brain areas, 
such as in the olfactory bulb, cortex, hippocampus and cerebellum. Using cortical 
primary culture labelled with TRITC-phalloidin to stain F-actin, they observed that CAP2 
colocalizes with F-actin. In particular, they showed that CAP2 also localizes in the 
dendritic shaft and presynaptic terminal with a synapsin I staining and in the excitatory 
postsynaptic sites, with a PSD-95 co-staining. Mutant mice showed a statistically 
significant increase in dendritic arbor complexity using a Sholl analysis respect to 
control. That results were confirmed by F/G actin ratio analysis, that shows an increase 
of the ratio in the mutant brain lysates. The authors found out that the induction of 
chemically long term potentiation (cLTP) results in a reduced surface density of GluA1 
compared to the surface GluA1 in WT cortical neurons, which suggests that the synaptic 
plasticity is impaired in CAP2 mutant neurons. This was further analysed with a surface 
biotinylation assays, suggesting that CAP2 is important for the exocytosis of AMPA 
receptor. Since previous studies reported that CAP2 modulate the dissociation of ADP 
G-actin-cofilin complexes136, they verified if CAP2 was able to bind cofilin. They 
confirmed the CAP2-n-cofilin interaction and found out that ablation of CAP2 in neuron 
results in the reduction of phosphorylated (inactive) cofilin and its accumulation in 
cytoplasmic aggregates cells168. 
A lot of studies reported that the gene of CAP2 is up-regulated in the early phases of 
Hepatocellular carcinoma (HCC)169. Shibata and co-workers have studied the 
expression of CAP2 and demonstrated its overexpression in multistage carcinogenesis 
of HCC. It was assumed that the stromal invasion capacity that occurs in the early 
months of HCC could be related to the actin binding activity of CAP2. The CAP2 
involvement in other carcinomas remains unclear. Peche and collaborators170 
monitored mRNA levels in 47 different types of cancer. CAP2 was over up-regulated in 
renal cancer, brain, colon, bladder and thyroid, while it was down-regulated in breast 
cancer, suggesting that CAP2 is regulated in different ways according to the type and 
origin of the tumour. 
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1.3 SYNAPTIC PLASTICITY: HOW THE SYNAPSES STORE 
INFORMATION 
Various factors can modify the strength of the transmission of the synapses. The 
synaptic activity is the capability of two neurons to communicate each other. Specific 
patterns of synaptic activity can modulate the strength of the synaptic transmission and, 
by this sophisticated way, the synapses store information in response to experience. 
The capability to modify neuronal circuit function generated by the experience is called 
synaptic plasticity. This term also includes the role in creating new circuits during the 
development and the capability to maintain the normal physiology of the neuronal 
circuits created171. 
 
1.3.1 SHORT-TERM PLASTICITY 
The short-term plasticity is characterised by an increase in the probability of transmitter 
release, in response to the left over calcium concentration in the presynaptic side after 
short bursts of activity. The major function of the short-term plasticity is to modulate the 
filter capability of the synapses, inhibiting or enhancing the release probability of 
neurotransmitter171. 
In particular, the paired pulse facilitation /depression is a form of short-term plasticity. It 
is a facilitation or a depression of the synaptic transmission depending on the timing at 
which a second stimulus is delivered after a first one on the same synapse; it’s a paired-
pulse facilitation if the second stimulus occurs within an interval from the first of 20–500 
ms, while the paired pulse depression occurs after a shorter interval (less than 20 ms)172 
173. Facilitation can be attributed to an increase of calcium concentration produced by 
the second stimulus leading to an increased probability to facilitate an additional release 
of neurotransmitter after the first stimulus. A lot of protein of the presynaptic 
compartment can contribute to promote the short-term plasticity, in particular the 
activation of protein kinases can modulate the activity of presynaptic phosphoprotein, 
for example synapsin174. On the other hand, a strong depletion of calcium in the 
presynaptic compartment can be generated after the first stimulus, contributing to 
create a depression. Indeed, paired-pulse depression is commonly observed in all 
synapses after short (less than 20 ms) interstimulus intervals, and it probably results 
from the inactivation of voltage-dependent sodium or calcium channels or from a 
	 24	
transient depletion of the release-ready pool of vesicles docked at the presynaptic 
terminal. Actually, we can point out that the depression, rather than facilitation, is strictly 
related to the transmitter release; in fact, in synapses where the probability of 
neurotransmitter release is high, the phenomena of depression may predominate171. 
Other forms of short-term plasticity are the post-tetanic potentiation (PTP) and the 
augmentation. The PTP occurs after a repetitive or tetanic stimulation of synapses with 
prolonged (approximately 200 ms to 5 s) trains of stimulation applied at high frequencies 
(10–200 Hz)173. On the other hand, repetitive activation leads to depression that can 
last for several seconds or even minutes173. Augmentation and PTP describe an 
enhancement of transmitter release lasting from seconds (augmentation) to several 
minutes (PTP)171. The concentration of Ca2+ in terminal boutons rises during PTP, 
suggesting that, like facilitation, it is a presynaptic process. 
Moreover, the G protein–coupled receptors (GPCRs) play an important role in the 
modulation of the synaptic transmission, enhancing or depressing it. In addition,  
several neuromodulators can influence the presynaptic release: retrograde messengers 
that have been identified in specific cell types include dopamine, dynorphin, glutamate, 
GABA, nitric oxide, brain-derived neurotrophic factor (BDNF), and oxytocin175-178. 
Astrocytes and perisynaptic Schwann cells regulate the synapses because of their 
intimate association with them. They have different roles, such as the clearance of 
neurotransmitter, thus controlling the speed and the extent of such clearance (Bergles 
et al, 1999; Danbolt, 2001). The glia can act on the short-term plasticity releasing 
substances that can impact on the synaptic function, including extracellular 
messengers; in particular, glial cells have different receptors, including Ca2+-permeable 
channels, that can control the internal stores of [Ca2+]i. The resulting increase in [Ca2+]i 
can trigger vesicular release of substances from astrocytes, which can act on 
presynaptic terminals to regulate neurotransmitter release173. 
 
1.3.2 LONG-TERM PLASTICITY 
 
1.3.2.1 LONG TERM POTENTIATION 
LTP is a persistent increase in synaptic strength following a high-frequency stimulation 
of a chemical synapse. First it was described by Bliss and colleagues179,180. It has been 
reported that the repetitive activation of excitatory synapses in the hippocampus causes 
a potentiation of synaptic strength that could last for hours or even days. Nowadays, we 
know that there are different forms of LTP in several brain areas, in particular at the 
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glutamatergic synapses and the form of LTP that occurs in the hippocampus, between 
the Shaffer collateral (axons that derive from the cells in CA3) and the apical dendrites 
of CA1 pyramidal cells, is considered the prototypic system to explain the LTP that 
appears at the glutamatergic synapses. LTP is characterized by three basic properties: 
cooperativity, associativity and input-specificity. Cooperativity means that several 
presynaptic fibres must be activated to generate the trigger signal. Moreover, the LTP 
is associative, which means that strong activation of one set of synapses can facilitate 
LTP at an independent set of adjacent active synapses on the same cell if both sets of 
synapses are activated within a finite temporal window181. Finally, LTP is input-specific, 
because when the trigger signal is turned on, all the others stimuli can’t be active. Many 
type of LTP have been described in the hippocampus, but the most described is 
NMDAR dependent. According to that, the induction of the LTP needs the increase in 
postsynaptic calcium concentration through NMDARs during a strong postsynaptic 
depolarisation of the cell181. In this process, the entry of the Ca2+ triggers the 
translocation of specific proteins to the synapse, including the AMPAR182. Practically 
the electrical stimulation, achieved with a high-frequency train of stimuli to the Schaffer 
collaterals, can generate, in the CA1 cells, excitatory postsynaptic potentials (EPSP). 
High-frequency stimulation protocols typically comprise delivery of one or several trains 
of pulses at 50–100 Hz for 1 sec183, called tetanic stimulation. This strong stimulation 
that leads to a summation of the excitatory postsynaptic potentials (EPSPs) allows 
achieving a strong depolarisation of the postsynaptic cell, activating NMDARs. In the 
early phase of LTP there is a strong redistribution of AMPARs at the synapse, because 
of activity-dependent changes in AMPAR trafficking, and this events are required for 
the maintenance of LTP 181,184-186. For example, the proteins of the TARP family control 
AMPAR distribution and insertion187 188,189. The molecular mechanism by which the LTP 
is maintained is initiated by a sufficient depolarisation of the membrane that allows the 
Mg2+ removal and the influx of the Ca2+ ion through NMDAR. The calcium ions activate 
intracellular kinases and phosphatases, such as PKA, PKC and CAMKII. 
In particular, CAMKII is activated by a structural change and it is recruited to the PSD, 
where it can phosphorylate several proteins such as AMPAR, NMDAR, PSD-95 190. The 
phosphorylation of Ser73 of PSD-95 can dissociated the PSD-95 from GluN2A while 
the phosphorylation of Ser295 can increase the stability of the association of the two 
proteins191. Also AMPARs are modified by several phosphorylations that impact on its 
trafficking and channel properties. 
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The late phase of LTP is more persistent (lasting > 8 hr) and requires transcription and 
synthesis of new proteins and, therefore, takes advantage of the protein synthetic 
machinery at synaptic sites on dendrites. During the late phase of LTP, the molecules 
that mediate the signalling to the nucleus are CAMKII, PKA, CAMKIV and MAPK, which 
in turn activate the key transcription factor CREB. However, the local synthesis 
apparatus can also be involeved in the generation of proteins that play a key role in the 
modifications triggered by LTP. Harris and co-workers showed that the percentage of 
spines containing polyribosomes increased 2 h after a tetanic stimulation192. As 
described, the synthesis and transport of new proteins enriches the composition of the 
spines. One of the most accredited hypothesis regarding the specificity of the new 
protein localisation is the capability of LTP to generate the so called “synaptic tag”, 
responsible for capturing the proteins and molecules only into selected spines193. The 
nature and composition of this synaptic tag is still unknown and object of debate, even 
if Morris and colleagues proposed anatomical changes and phosphorylation of 
receptors and kinases as possible tag candidates. 
Eva Fifkovà described for the first time, by the EM microscopy, that the enlargement in 
the morphology of the spine was correlated to the LTP. This modification in spine 
morphology was found 2 min after tetanic stimulation and lasted up to 23 h194. 
Matsuzaki confirmed these data using photolysis of caged glutamate and imaged it by 
two-photon microscopy. He demonstrated that, in the hippocampus, LTP leads to an 
enlargement of the dendritic spines that is correlated with an increase in the synaptic 
electrical response. Moreover, it has demonstrated that the LTP can induce new spine 
formation195. Along with spine growth, morphological changes associated with LTP 
include enlargement of the PSD196, the splitting of the single PSDs and spines into two 
functional synapses197,198, the remodelling of spine actin cytoskeleton199, redistribution 
of polyribosomes200 and mitochondria201. 
In addition to the prototypic LTP described above, in the hippocampus another form of 
LTP has been described and occurs at the mossy fiber synapses, the synapses 
between the axons of dentate gyrus granule cells (i.e., mossy fibers) and the proximal 
apical dendrites of CA3 pyramidal cells181. As for the NMDARs mediated plasticity, this 
LTP can represent a paradigmatic example of forms of plasticity that occurs also in 
other areas of the brain. The trigger of mossy fiber LTP is an increase in intracellular 
calcium concentration in presynaptic terminals202-204. The involvement of the 
presynaptic kainate receptor205-207  that leads to an increased probability of 
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neurotransmitter release is clear. Like NMDAR-dependent LTP, new protein synthesis 
appears to be required for maintaining mossy fibre LTP. However, it is unknown 
whether the increase in PKA activity following the induction of mossy fibre LTP is 
maintained for tens of minutes or hours. We also do not know whether long-lasting 
structural changes occur at the synapses that express mossy fibre LTP (Fig.3).  
1.3.2.2 LONG TERM DEPRESSION 
LTD (long term depression) has been considered as a parallel and opposite process to 
the more common LTP55. There are different forms of LTD through the brain, but, as I 
mentioned above, I will focus on the NMDAR-dependent LTD at excitatory synapses on 
hippocampal CA1 pyramidal cells208. 
We can induce LTD in neuronal cells applying a prolonged repetitive low frequency 
stimulation protocol; NMDAR-dependent LTD can also be induced by correctly timing 
the activation of presynaptic axons and the postsynaptic neuron209 (STDP). As the LTP, 
also the LTD is input-specific depending on the postsynaptic concentration of 
calcium210. The difference between the two processes resides in the difference in the 
concentration of calcium: high concentration of calcium triggers LTP, low concentration 
of calcium triggers LTD. The low frequency stimulation that leads to LTD involves the 
activation of calcium/calmodulin-dependent phosphatase calcineurin (also known as 
protein phosphatase 2B), of PP1, and of a phosphoprotein inhibitor-1 which inhibits PP1 
until calcineurin dephosphorylates it; it also inhibits and prevents the phosphorylation 
of several proteins, such as PKC and PKA. Consistent with a role for PKA, LTD is 
associated with selective dephosphorylation of Ser845 on GluR1, a PKA substrate site 
211(Lee et al, 2000). This dephosphorylation event may contribute to the expression of 
LTD, as it decreases the AMPAR open-channel probability212. 
Indeed, LTP is associated with phosphorylation of GluR1-Ser831, a substrate of 
CAMKII and PKC. While LTD was found to be associated with selective 
dephosphorylation of GluR1-Ser845 without any change in GluR1-Ser831208. The LTD 
induction in the CA1 cells can also trigger an activation of metabotropic glutamate 
receptors. Probably the extrasynaptic group of mGluRs are responsible for activating 
this kind of LTD213, including the mGluR1 and mGluR5 G-coupled protein receptors. In 
particular, it has been shown that the mGluR1 can activate the LTD in the ventral 
tegmental area (VTA), while the mGluR5 is involved in the hippocampus, cortex, and 
nucleus accumbens LTD induction171. In the cerebellum and in the VTA, the PKC 
mediates this kind of LTD213, but probably it is not involved in the mGluR- mediated LTD 
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in the hippocampus. Other signalling proteins important for mGluR LTD include the 
MAPKs p38, ERK, and Jnk214-216, tyrosine phosphatases217, and phosphatidylinositol 3-
kinase218 but how these various enzymes might lead to a long-lasting decrease in 
synaptic strength is unknown171. It is not clear where the mGluR-mediated LTD takes 
place. It has been suggested that in slices prepared from neonatal (P8–P15) animals, 
mGluR LTD is independent from protein synthesis and is due to a presynaptic 
modification, whereas in older animals (P21–P35) mGluR LTD is mediated by a protein 
synthesis-dependent reduction in the postsynaptic levels of AMPARs171. In particular, 
in the hippocampus the mGlur5 receptors stimulates the initiation of the local synthesis 
thought the Homer scaffold protein219 (Fig.3). 
 
 
1.3.3 Other mechanisms for plasticity: tuning the synapses  
Additional forms of synaptic plasticity that are not activity dependent have been 
identified, such as metaplasticity and homeostatic plasticity220. The homeostatic 
plasticity is the capability of neurons of regulating their own excitability relative to 
network activity, it uses a much slower timescale than LTP and is probably very 
important for the development. A mechanism, by which the homeostatic plasticity may 
allow local changes, is the synaptic scaling, which uses a set of calcium-dependent 
sensors that regulate receptor trafficking to increase or decrease the accumulation of 
glutamate receptors in the spine221. The metaplasticity consists in the ability of the 
neurons to modulate the activity-dependent synaptic plasticity222, or in other words the 
LTP or LTD are regulated by a plasticity of the entire synaptic state. In fact, now we 
know that there is a threshold for a system to induce the synaptic plasticity, and this 
movement within the plasma membrane. Most investigators
believe that the incorporation of AMPARs into the PSD is
the more important change because it appears to be
accompanied by structural changes in the dendritic spines
and synapses themselves, an attractive mechanism for
maintaining LTP (see below). There re also experimental
findings consistent with rapid presynaptic changes during
LTP, but the retrograde messenger that is responsible
remains elusive, one prominent possibility being BDNF
(Bramham and Messaoudi, 2005).
Maintaining LTP. Much of the work on NMDAR-
dependent LTP has focused on the mechanisms responsible
for its initial 30–60min, to a large extent because of
technical limitations in the duration over which stable
electrophysiological recordings can be maintained. None-
theless, the mechanisms that allow LTP to persist for hours,
days, or even longer are of great importance. Like virtually
all cell biological phenomena, the persistence of LTP is
dependent upon new protein synthesis (Reymann and Frey,
2007). This so-called ‘late phase of LTP’ (defined as the
pot ntiation present more than 1–2 h after LTP induction)
is commonly assumed to depend upon local dendritic
protein synthesis, which supplies needed components to the
synapse (Sutton and Schuman, 2006), as well as transcrip-
tion in the nucleus (Zhou et al, 2006). The signaling to the
nucleus required for long-lasting LTP has been suggested to
depend on a number of protein kinases including PKA,
CaMKIV, and Erk-MAPK, which activate key transcription
factors that may include cAMP response element-binding
protein and immediate-early genes such as c-Fos and
Zif268/Egr-1 (Thomas and Huganir, 2004). These transcrip-
tional complexes presumably promote expression of
effector genes that are required for maintaining the synaptic
enhancement.
Several mRNAs can be found in dendrites, including
those of the AMPARs themselves, CaMKII, Arc, and
proteins which may function to regulate receptor trafficking
(Grooms et al, 2006; Job and Eberwine, 2001; Ju et al, 2004;
Mayford et al, 1996; Schuman et al, 2006; Steward and
Schuman, 2001). The trafficking of some of these mRNAs
and their local translation seems to be highly regulated by
activity. Furthermore, other components of the translational
machiner are found in or adjacent to dendritic spines and
polyribosomes are recruited to spine heads following LTP
induction (Bourne et al, 2007). Thus, there is accumulating
evidence that the machinery to provide local, newly
synthesized proteins to synapses is available.
An intriguing hypothesis is that during the synaptic
activation to induce LTP a ‘synaptic tag’ is generated that
functions to capture or sequester plasticity related proteins,
which in turn are required to stabilize the increase in
synaptic strength (Frey and Morris, 1997). However, little is
known about the identity of the synaptic tag or the newly
synthesized proteins that are required to maintain LTP,
although it has been suggested that PKA, CAMKII, or PKMz
might function as the synaptic tag (Reymann and Frey,
2007; Sajikumar et al, 2005; Young et al, 2006).
A compelling possibility for a long-term maintenance
mechanism of LTP is the structural remodeling of
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Figure 2 Model of AMPAR trafficking during LTP and LTD. In the basal state (depicted on top), receptors cycle between the postsynaptic membrane and
intracellular compartments. This is achieved through lateral mobility of the receptors out of the synapse into endocytic zones, where they are endocytosed
into early endosomes in a clathrin- and dynamin-dependent manner. Normally, the receptors are transferred to recycling endosomes and returned to the
plasma membrane by exocytosis, followed by lateral movement into the synapse where they are retained through interaction with MAGUKs. Following
induction of LTP, there is enhanced receptor exocytosis and stabilization at the synapse through a calcium-driven process that involves CAMKII and fusion of
recycling endosomes mediated by Rab11a. Following the induction of LTD, enhanced endocytosis at extrasynaptic sites occurs in a process that is calcium-
dependent and involves protein phosphatases, primarily calcineurin and protein phosphatases 1 (PP1). While in the basal state endocytosis is presumably
balanced by receptor recycling, following LTD receptors are retained within the cell, and perhaps degraded.
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limit is not a static property of synaptic connections but, instead, changes dynamically 
according to the recent history of synaptic activity 222. 
1.3.4 SYNAPTIC PLASTICITY: THE BASIS OF MEMORY 
According to Bear and Malenka (2004), the brain takes advantage of the neuronal 
capability to express long-lasting activity-dependent synaptic modifications as one of 
the key mechanisms by which experiences modify neural circuits behaviour.  However, 
in the last years, the LTP phenomenon has been the object of intense investigation 
because is considered to be the basis of the process of memory formation. Indeed, 
since the hippocampus is a well-known locus for declarative memory223, it is not 
surprising that in the last three decades a major effort aimed at demonstrating a role for 
hippocampal LTP in encoding new memories224. According to such hypothesis, the 
process of strengthening the synapses can increase the strength of circuits' 
connections thus leading to the storage of the new information in those circuits (i.e. in 
particular in the hippocampus, the declarative memory, the type of memory that, in 
humans, can be consciously recalled, is generated). During the last years, several 
correlations have been observed between defective hippocampal synaptic plasticity 
and defective hippocampal-dependent memory tasks upon perturbation of a number of 
proteins which have a role in synaptic plasticity, either pharmacologically, or through 
gene knockout 225. 
 
1.3.5 SPINES ARE ELECTRICAL COMPARTMENTS 
Spines are clearly electrical compartments separated from the parents' dendrite 54. It is 
clear that during the APs (Action Potentials) the voltage of the spines is present also in 
the parents' shafts, whereas during excitatory postsynaptic potentials (EPSPs) spines 
must sustain a higher depolarization than dendritic shafts. Probably this occurs thanks 
to the particular shape of the spines: the most plausible hypothesis is that the action 
potential is amplified in the head of the spine and reduced as it invades the shafts by 
passing through the neck. There are still different hypothesis on how the electrical 
compartmentalisation is kept. In any case, it allows the spine to amplify the synaptic 
currents and reduce the EPSPs when they invade the dendrites thus preventing the 
dendrites saturation, especially if the neuron integrates a lot of inputs. Alternatively, this 
phenomenon can be interpreted as a mechanism through which spines could simply 
diminish the depolarization generated by each input, therefore more EPSPs can be 
integrated before the neuron fires an AP. Moreover, the electrical compartmentalization 
enables precise control of the synaptic strength. This process could occur by modifying 
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the amplification of EPSPs at the spine head, by altering the activation of spine 
conductance, or by altering the spine neck/dendritic shaft electrical coupling by either 
active or passive mechanisms. For this reason, after the LTP induction we can clearly 
see the modification of the morphology of the spine that allows the spines to be more 
responsive to the external signal 49. A compelling possibility for a long-term 
maintenance mechanism of LTP is the structural remodelling of potentiated synapses 
183. Spines have a variety of shapes and sizes, and can undergo rapid shape changes 
that are influenced by activity198. Morphological changes, which have been reported to 
accompany LTP, include growth of new dendritic spines, enlargement of pre-existing 
spines and their PSDs, and the splitting of single PSDs and spines into two functional 
synapses 195,197,198. An attractive model suggests that during LTP, recycling endosomes 
contribute to AMPAR subunits insertion in the synapse, as well as to lipids and 
constituents enrichment which enlarge the synapse226,227. At later time points, there is 
a concomitant increase in the presynaptic active zone, the size of which always closely 
matches to that of the PSD226. This presynaptic remodelling must involve post- and 
presynaptic protein interactions with cell adhesion molecules. 
 
1.3.6 ACTIN ROLE IN PLASTICITY 
It has been shown that the neuronal plasticity is strictly linked to the fast remodelling of 
the synaptic actin228. LTP induction moves the G and F actin ratio to an increase in F-
actin levels leading to an increase of spine volume, while the LTD induction move the 
ratio toward an increase of the G-actin concentration leading to the shrinkage of the 
spine199,229. The link between the LTP and actin remodelling is demonstrated by the 
treatment with depolymerizing actin reagents195,229. Bosh and colleagues showed for 
the first time, the remodelling that occurs in the spine after the LTP stimulation. 20 
seconds after the LTP induction there is a rapid increase of the actin levels in the spines. 
Moreover, there is also a change in the composition of the actin binding proteins that 
regulate the actin cytoskeleton into the spine. During the first minutes of LTP induction, 
the concentration of a lot of protein that can modify the actin cytoskeleton, such as 
debrin, CaMKIIβ e α-actinin, is decreased230 . During this phase, that takes 1-7 
minutes194, the actin cytoskeleton is more unstable and susceptible to reorganization. 
During this phase the cofilin plays an important role in the remodelling of F-actin. First 
of all, upon the activation of the NMDAR the cofilin is translocated to the synapse. Since 
the actin concentration is high, the cofilin can severe the actin cytoskeleton, leading to 
	 31	
the formation of new barbed ends231. The severing is a phenomenon that allows Arp2/3 
to enhance its function of branching, creating new filaments that are involved in the 
maintenance of spine expansion and in the proteins trafficking, such as the trafficking 
of AMPAR232. According to that, the pharmacological inhibition of the cofilin 
phosphorylation prevents the maintenance of spine enlargement, even if the first phase 
of the LTP is not blocked. Indeed, Bosch proposes the fundamental role for cofilin and 
others ABP for the maintenance of the structural remodelling of the actin cytoskeleton. 
During the second phase (7-60 min after the LTP induction) the actin concentration 
goes back to “normal” levels. In this phase all the changes that occured in the first phase 
are stabilized. According to that, the cofilin moves to the neck of the spine after its 
phosphorylation on Ser3. This is a key point, since if the cofilin phosphorylation is 
prevented, it is possible to assist to an excessive severing process that can lead to the 
spine shrinkage, fostering the depolymerisation of actin instead of polymerisation233. In 
the neck of the spine, the cofilin is dephosphorylated again in order to bind F-actin and 
create a stable structure, made of cofilin and F-actin, at the base of the spine head. This 
particular complex, in the neck, can decrease the normal movement of F-actin from the 
spine head234. Indeed, the complex cofilin-actin can stop this treadmilling leading to the 
enlargement of the spine at the spine head. Moreover, the importance of F actin is not 
only related to the remodelling, but after LTP induction it can capture and stabilize a lot 
of proteins, thus representing an anchoring for several molecules235. In the third phase 
(that correspond to L-LTP, late LTP), that occurs 60 minutes after induction, there is a 
stabilization of the spine composition. In particular, synaptic proteins, as the members 
of MAGUK family, reach a level that is proportional and closer to the new spine volume, 
thus the natural correlation between the volume and the PSD size is recovered 236 (Fig. 
4). 
As concern the structure of the spines, it has been demonstrated that the F-actin 
nucleation, mediated by WAVE complex, an activator of the Arp2/3 complex, occurs in 
the central structure of the spine, while the elongation occurs at the tip of finger-like 
protrusions. For that reason, the proteins involved in the branching of the already 
assembled filaments are localized in the central part of the PSD, while next to the 
membrane the filament elongator proteins are localized. The synaptic plasticity, 
modifying the distribution patterns of ABP, induces also the redistribution of branched 
F-actin regulators in spines, to create an enlargement also in the distal part of the spine 
237. 
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	  of spines closer to the neck while the fast treadmilling of
actin filaments closer to the spine head surface fine-tunes
spine shape and dynamics, conferring a capability to
respond to stimuli [Koskinen et al., 2014]. Thus, increased
myosin IIb expression and spine localization during neuro-
nal maturation [Ryu et al., 2006] can explain the detected
increase in the relative size of the F-actin stable pool (actin
crosslinking) and the faster treadmilling of the dynamic
pool (myosin IIb motor activity) in 3-week-old compared
to 2-week-old neurons [Koskinen et al., 2014] (Fig. 1).
Actin Dynamics During Long-Term
Potentiation
Proposed as being the cellular counterpart for memory for-
mation, it is not surprising that LTP and the associated
spine remodeling have recently got a lot of attention. Trains
of high-frequency activity can induce long-term potentia-
tion (LTP) of glutamatergic synaptic connections: a persis-
tent increase in the strength of a synapse. It is mediated by
membrane depolarization, NMDA receptor activation and
short, significant increases in postsynaptic calcium [Huganir
and Nicoll, 2013]. LTP formation relies on dynamic actin
filaments [Krucker et al., 2000; Fonseca, 2012]. During
LTP, dendritic spines accumulate F-actin and these changes
can persist for weeks, along with an increase in the ampli-
tude of synaptic currents [Fukazawa et al., 2003]. Single
spines undergoing LTP exhibit a significant expansion of
the spine head along with a shortening and widening of the
spine neck [Matsuzaki et al., 2004; Urban et al., 2011;
Tønnesen et al., 2014].
Phase I: Reorganization of the Spine
Actin Cytoskeleton
Spine remodeling during LTP follows several phases (Fig. 2).
First, almost immediately after stimulation (1–7 min), the
spine head rapidly enlarges, F-actin concentration rises and
actin-severing/depolymerizing, -capping and -polymerizing
proteins enter the spine while actin-stabilizing proteins leave
[Matsuzaki et al., 2004; Okamoto et al., 2004; Honkura
et al., 2008; Bosch et al., 2014; Meyer et al., 2014; Mizui
et al., 2014]. Such neuronal activation also results in the auto-
phosphorylation of CaMKIIb and, subsequently, its dissocia-
tion from F-actin [Kim et al., 2015b]. CaMKIIb can
stabilize and maintain spine structure through actin bundling
and by inhibiting the binding of other actin regulators
[Okamoto et al., 2007; Kim et al., 2015b]. Dissociation of
CaMKIIb releases the maintenance of the actin structures
allowing for reconstruction. The characteristics of this initial
step illustrate how synaptic activity can orchestrate the action
of tens of actin-regulatory proteins to destabilize and partly
break down the existing actin structure in order to rebuild it
according to the new needs (Fig. 2). Active cofilin is especially
highly enriched in spines in this first stage, suggesting a major
Fig. 2. Dendritic spine actin dynamics in long-term potentiation formation. Immediately after high-frequency stimulation (HFS),
Ca21 ions flow into spines. Actin filaments are cut shorter through severing (scissors) while actin polymerization expands the spine
head (yellow circles). Soon after this initial enlargement, actin filaments are gradually stabilized and spine head size decreases.
We propose that cytoskeleton breakdown allows for the effective addition and replacement of AMPA receptors while re-stabilization
facilitates the maintenance of these changes.
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I.Hlushchenko	et	al.,Cytoskeleton-2016	
Figure	4.	Actin	remodelling	during	LTP 
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1.4 ADAM10: AN ENZYME INVOLVED IN SEVERAL 
SYNAPTOPATHIES 
Neuronal signalling is an integrated process between the excitatory and inhibitory 
process. The signals that a neuron can receive could be excitatory or inhibitory, can be 
directed to the dendrites or to the cell body, and whether the neuron fires an action 
potential depends on the total input of all the synapses238. There are a lot of control 
mechanisms that maintain the balance between the excitatory and inhibitory synaptic 
transmission, the so-called E/I balance. Alteration in the E/I synapse balance has been 
proposed to be involved in the pathogenesis of many brain disorders, including autism 
and schizophrenia238. Moreover, it is known that the functional morphology of the spine 
is strictly linked to the synaptic function and therefore the deep comprehension of the 
mechanisms underlying the physiology of the synapse can help in the understanding of 
the basic mechanisms involved in the brain pathology. Spine morphology depends on 
rapid alteration in neuronal activity and glutamate receptor activation. Indeed, as 
described in the previous chapter, the induction of LTP causes enlargement of spine 
heads, whereas activity patterns that induce LTD cause spine head shrinkage238. 
A class of enzymes, such as the metalloproteases, responsible for the modulation of 
the synaptic morphology plays a specific role in the synaptic development and 
remodelling. For example, ADAM10 is involved in physiological processes such as the 
development to pathologies as AD. Indeed, the knockout mice for ADAM10 are 
characterized by prenatal lethality at 9.5 days of embryogenesis, with defects in the 
development of the central nervous system239. 
 
1.4.1 ADAM10 substrates 
The proteases (also called peptidase or proteinase) are enzymes that performs 
proteolysis; proteases play a critical roles the brain having emerging roles in synaptic 
plasticity, memory, neurodegenerative disorders such as Alzheimer’s, Parkinson’s and 
prion diseases, ischemia and traumatic brain injury, inflammatory and infectious 
diseases, and tumour progression. 
In the central nervous system (CNS), ADAM10 can cleave different proteins, among 
which: prion protein (PrP), N-Cadherin, neuroregulin, ephrins, L1 adhesion molecule, 
transmembrane chemokines, Notch and its ligand Delta and APP (Amyloid Precursor 
Protein).  
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The prion protein (PrP)  
The cellular prion protein PrP is essential for the pathogenesis and transmission of prion 
diseases. Whereas the majority of PrP is bound to the cell membrane via a 
glycosylphosphatidylinositol (GPI) anchor, a secreted form of the protein has been 
identified. PrP can be released into the medium by both protease and phospholipase-
mediated mechanisms240 (Parkin et al., 2004). PrP undergoes constitutive cleavage 
involving ADAM10 and phorbol ester-regulated proteolytic cleavage mediated by 
ADAM17 (Vincent, 2004). Therefore, activation of ADAM10 and ADAM17 could be 
considered a putative therapeutic strategy aiming at increasing normal PrP breakdown 
and, thereby, depleting cells of the putative toxic domain of PrP241. 
 
Adhesion molecules: N-Cadherin,  γ-protocadherins and L1 
Cadherins are Ca2+ dependent adhesion molecules expressed virtually by all cells that 
form solid tissue, during development as well as in adult life. N-Cadherin, the most 
abundant Cadherin in the CNS, belongs to type I classical Cadherins. The release of 
its extracellular domain, which contains the homophilic binding site, is functionally of 
major importance for the regulation of cell adhesion, cell migration and neurite 
outgrowth 242,243. ADAM10 is responsible for the initial proteolytic cleavage of N-
Cadherin, leading to the release of the extracellular soluble domain and the production 
of the membrane-bound carboxy-terminal fragment CTF1, which is cleaved by Υ-
secretase244. The enzymatic activity of ADAM10 on N-Cadherin may be significant for 
the coordinated interplay between cell-cell adhesion, cell detachment, cell proliferation 
and cell survival during embryogenic development, in wound healing and during tumour 
invasion. Other than N-Cadherin, at least two classes of cell-adhesion molecules are 
cleaved by ADAM10, γ-protocadherins (Pcdh-γ) and L1 adhesion molecule. Pcdh-γ are 
abundantly expressed in the nervous system. They are enriched at synapses and 
involved in synapse formation, specification and maintenance. Pcdh-γ C3 and Pcdh-γ 
B4 are constitutively cleaved within their ectodomains by ADAM10, thus inhibiting cell 
aggregation245. The immunoglobulin superfamily recognition molecule L1 promotes 
neuronal migration, neuronal survival and neurite outgrowth246. L1 undergoes 
constitutive cleavage at the cell surface which can be enhanced by stimulation with 
PMA, cholesterol depletion or NMDA-treatment (Maretzky et al., 2005; Mechtersheimer 
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et al., 2001). Constitutive and NMDA-induced shedding of L1 is mediated by ADAM10 
while PMA stimulation or cholesterol depletion leads to ADAM17-mediated L1 
cleavage247. ADAM10-mediated release was found to occur in intracellular vesicles that 
are subsequently released while cleavage of L1 in response to PMA occurred at the 
cell surface248. Soluble L1 has been shown to stimulate cellular migration, neurite 
outgrowth and recovery after spinal cord injury. 
 
Ephrin family 
Ephrins are neuronal guidance molecules that bind to receptor tyrosine kinases of the 
Eph family. Ephrin cleavage is fascinating. Ephrin ligands, presented on one cell 
surface, associate with their receptors on the surface of a juxtaposed cell, leading to 
cell-cell repulsion. Ephrin ligand can be proteolytically released from its membrane by 
a complex on the opposing cell composed of the ephrin receptor and ADAM10. While 
ADAM10 constitutively associates with EphA3, the formation of a functional 
EphA3/ephrin-A5 complex creates a new molecular recognition motif for the ADAM10 
cysteine-rich domain that positions the proteinase domain for effective ephrin-A5 
cleavage. Surprisingly, the cleavage occurs in trans, with ADAM10 and its substrate 
being on the membranes of opposing cells, suggesting a simple mechanism for 
regulating ADAM10-mediated ephrin proteolysis, which ensures that only Eph-bound 
ephrins are recognized and cleaved249. In particular, when the growth cone of a neuron 
that expresses Eph receptors encounters ephrin ligands on the surface of another cell, 
this event initiates bidirectional signalling cascades that regulate cell adhesion, axonal 
guidance and neuronal plasticity. The growth cone then overcomes these adhesive 
forces and breaks away from the ephrin surface by proteolytic shedding of ephrin. A 
cleavage-inhibiting mutation within ephrin A2 delays axon detachment, suggesting that 
shedding is critical for axon guidance in the CNS250. ADAM10 can cleave ephrin A5 
bound to EphA3 and thus terminate binding via ephrin. Notably, the ephrin receptor 
EphB2 also undergoes calcium-influx and NMDAR-induced cleavage that is sensitive 
to ADAM10 inhibition249. Thus, ADAM10 can be regarded as promoter of axon guidance 
and extension in the CNS because of the cleavage of ephrins as well as of their 
receptors.  
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Notch  
The receptor Notch and its ligand Delta 1 are required for neuroepithelial development 
during embryogenesis, but also for neuronal stem cell maintenance and self-renewal of 
the adult brain. ADAM10 cleaves the extracellular domain of Notch239  which is then 
directly followed by an intramembranous cleavage of the remaining cell-associated 
Notch molecule via γ-secretase. This results in the generation of a cytoplasmic fragment 
which can translocate into the nucleus and can be a transcription factor251. Thus, 
ADAM10 is critically involved in the transcriptional signalling pathway of Notch and is 
required for its functions in neurogenesis, even in the adult CNS.  
 
The Amyloid Precursor Protein (APP) 
Although APP is one of the most studied proteins, the physiological function of APP 
itself or indeed APP-derived peptides has not been definitively elucidated. Most 
evidence suggests that APP has a trophic function promoting neurite outgrowth, 
neuronal migration and repair via interaction with extracellular matrix proteins252,253. 
Several reports indicate that the lack of APP or its overexpression affects the number 
of dendritic spines. APP knockout mice exhibit a baseline dendritic spine density that is 
approximately two-fold higher compared with wild-type controls because of a higher 
number of persistent spines254. Moreover, dendritic spine density is modulated in a 
dose-dependent manner by APP expression. In addition to a role in spine morphology, 
two reports showed that APP may contribute to postsynaptic mechanisms via regulation 
of the surface trafficking of excitatory NMDA receptors255. 
Generation of Amyloid peptide (Aβ) from APP is positioned at the beginning of a 
cascade that leads to Alzheimer’s disease (AD). The shedding process is mediated by 
α- or β-secretases, while the cleavage of the membrane retained stubs is due to γ-
secretase3. β- and γ-secretases are the principal players involved in Aβ production, 
while α-secretase cleavage on APP prevents Aβ deposition. Three members of the 
family of ADAMs have been shown to exert α-secretase activity on APP: ADAM10, 
ADAM17, which is also known as TACE, i.e., Tumor Necrosis Factor-alpha Converting 
Enzyme, and ADAM9, also referred to as MDC9, standing for 
metalloprotease/disintegrin/cysteine-rich protein256,257. Two recent studies finally 
demonstrated that the constitutively cleaving α-secretase activity in neurons is 
selectively mediated by ADAM10258,259. ADAM10-mediated non amyloidogenic 
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pathway on APP releases one soluble, neurotrophic fragment called sAPPα and one 
membrane associated stub, called CTF83, which can then be cleaved by the γ-
secretase complex, liberating extracellular p3 and the amyloid precursor protein 
intracellular domain(AICD). 
 
1.4.2 ADAM10 structure 
ADAM10 is a 748 amino acid type I membrane glycoprotein, which is ubiquitously 
expressed260. Members of the ADAM family are characterized by a defined domain 
structure, including a signal sequence, a N-terminal prodomain, followed by a catalytic 
proteinase domain containing a zinc-binding motif, a disintegrin domain, a cysteine-rich 
sequence, a transmembrane domain, and a cytoplasmatic tail260. The nascent protein 
is not functional and is produced as a zymogene. ADAM10 is predominantly found as 
a proenzyme intracellularly in the Golgi, presumably in an inactive form257.  After the 
cleavage of the signal sequence, ADAM10 enters the secretory pathway to be 
processed and thereby activated by the proprotein convertases furin or PC7261, as 
demonstrated for the prodomains of several ADAMs262-264. Furin and PC7 are calcium-
dependent endoproteases responsible for proteolytic cleavage of cellular and viral 
proteins transported via the constitutive secretory pathway. Cleavage occurs at the C-
terminus of basic amino acid sequences, such as R–X–K/R–R and R–X–X–R. The furin 
was found predominantly in the trans-Golgi network (TGN), but also in clathrin-coated 
vesicles dispatched from the TGN, on the plasma membrane as an integral membrane 
protein and in the medium as an anchorless enzyme. ADAM10 prodomain exhibits a 
dual function: the separately expressed prodomain is capable of inactivating 
endogenous ADAM10 in cell cultures while overexpressed ADAM10 without its 
prodomain is inactive261. By contrast, coexpression of the prodomain in trans rescues 
the activity of the deletion mutant of ADAM10 lacking of the intracellular prodomain. In 
addition, the recombinant murine prodomain purified from Escherichia coli acts as a 
potent and selective competitive inhibitor in experiments performed in vitro265. This 
implicates that the prodomain of ADAM10 acts not only as a transient inhibitor, but also 
as an internal chaperone in the maturation of the enzyme. The catalytic domain of 
ADAM10 contains a typical zinc-binding consensus motif (HEXGHXX GXXHD); the 
mutation E384A compromises this motif and leads to a substantial decrease in sAPPα 
secretion266,267. Although the removal of the disintegrin domain of ADAM10 did not 
grossly affect shedding of APP in cell cultures, the cleavage of some substrates 
molecule is likely to be influenced by non-catalytic domains. For example, epidermal 
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growth factor cleavage is at least partially impaired in ADAM10 knockout cells 
overexpressing a cytoplasmic domain deletion mutant of ADAM10268. During transport 
through the secretory pathway, ADAM10 is complex N-glycosylated resulting in the 
active protease, which mediates proteolysis in the late compartments of the secretory 
pathway and at the plasma membrane. Cell surface biotinylation experiments 
demonstrated that the proteolytically activated form of ADAM10 is localized mainly in 
the plasma membrane257 (Fig. 5). 
 
 
1.4.3 Regulation of ADAM10 activity: the role of intracellular trafficking 
ADAM10, that is enriched in the PSD 269 can act on its substrate only when is correctly 
inserted into the plasma membrane. Therefore, the regulation of its trafficking can 
control its activity. Several proteins can modulate ADAM10 synaptic localization and, 
thereby, its activity. 
SAP97, a member of the MAGUK family, can modulate ADAM10 trafficking fostering its 
insertion in the synaptic membrane269. SAP97 SH3 domain binds to the proline-rich 
sequences in the cytosolic domain of ADAM10, thereby driving the protease trafficking 
from dendritic Golgi outposts to the postsynaptic membrane and increasing its cleavage 
activity. This process is mediated by a previously uncharacterized protein kinase C 
phosphosite in SAP97 SRC homology 3 domain that modulates SAP97 association with 
ADAM10. Such mechanism is essential for ADAM10 trafficking from the Golgi outposts 
to the synapse, but does not affect ADAM10 transport from the endoplasmic 
reticulum270. 
2. The gene locus and mRNA of ADAM10: place of
transcriptional regulation and translational control
The 16 exons of the mouse and human gene for ADAM10 are
located in a region of about 160 kbp on mouse chromosome 9 and
human chromosome 15, respectively (Yamazaki et al., 1997a,b)
(Fig. 1). Luciferase reporter assays were used to characterize the
promoter region which lacks a classical TATA motif. The region
between !508 and !300 was found to include binding sites for
Sp1, USF and also contains a retinoic acid-responsive element
(Fig. 2). An additional retinoic acid-responsive element is found
more downstream. In this context, vitamin A acid application to
cells increased the activity of the human ADAM10 promoter
(Prinzen et al., 2005).Within the ADAM10 promoter region, single-
nucleotide polymorphisms (SNPs) were not necessarily different
when AD patients and control subjects were compared (Prinzen
et al., 2005).
ADAM10 transcripts were found to be 4.4 kb in size. Careful
examination of the sequence of the mRNA of ADAM10 revealed an
untranslated 50 located GC-rich stretch of about 450 nucleotides.
Interestingly, the presence of this region inhibited the translation
of a reporter and vice versa a deletion caused, strongly increased
expression in human kidney cell lines (Lammich et al., 2010). The
translational repression due to this 50 UTR was caused by a stable
G-quadruplex RNA secondary structure (Lammich et al., 2011), and
Fig. 1. Evolution, gene structure, maturation and regulation of the ectodomain sheddase ADAM10. (A) The A Disintegrin AndMetalloproteinase family (ADAMs) is composed
of inactive and active proteases. ADAM10 and ADAM17 are closely related members of the active ADAMs. (B) The human ADAM10 gene consists of a 50 and 30 untranslated
region (blue) and 16 exons which are used to generate the multimodular ADAM10 polypeptide. ADAM10 is itself subject to ctodomain shedding (black arrow). The crystal
structure model of the disintegrin domain (Janes et al., 2005) within the extracellular domain of ADAM10 is depicted. (C) Furin cleavage within the Golgi removes the
prodomain of ADAM10 and leads to the mature and fully active form of the protease. Ectodomain shedding of substrates mediated by ADAM10 triggers intramembrane
proteolysis by theg-secretase complex or by signal peptide peptidase-like proteases (SPPLs). (D) Regulation of ADAM10 activity ismediated at different levels, i.e. modulation
of promoter activity, the degree of prodomain release, cellular trafficking, cellular signaling and lipid and protein interactions.
Fig. 2. Regulation of ADAM10 at the transcriptional and translational level. ADAM10
transcription is controlled by several transcription factors. Their binding sites in the
ADAM10promoter are indicated by colored squares. One factor is a heteromer of RAR
and RXR, which appears to bind to the indicated RXRmotif, butmay additionally also
bind to the other RXR motif (Prinzen et al., 2005). Upon binding of all-trans retinoic
acid (atRA) to RAR, the RAR/RXR factor stimulates ADAM10 transcription. The drug
acitretin, a retinoic acid derivative, is able to displace atRA from the cellular retinoic
acid binding protein (CRABP), leading to atRA binding to RAR and stimulation of
ADAM10 expression. The mRNA of ADAM10 consists of a GC-rich 50 untranslated
region (50 UTR), theADAM10open reading frame (ORF) and the 30 UTR. Twoupstream
open reading frames (uORFs, light blue boxes) are found in the 50 UTR, but do not
control ADAM10 translation. In contrast, a GC-rich G quadruplex (GQ) structure
suppresses ADAM10 translation, presumably through FMRP. Likewise, different
miRNAs suppress ADAM10 translationbybinding todifferent sequenceswithin the30
UTR. The length of 50 UTR, ORF and 30 UTR is not drawn to scale.
P. Saftig, S.F. Lichtenthaler / Progress in Neurobiology 135 (2015) 1–20 3
P.	Saftig,	S.F.	Lichtenthaler,	Progress	in	Neurobiology-2015	
Figure	5.	ADAM10	structure 
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The mechanism by which SAP97 mediates the ADAM10 trafficking, is regulated by 
LTD, one of the main paradigms of activity-dependent synaptic plasticity. Indeed, LTD 
boosts ADAM10 membrane insertion by fostering its SAP97-mediated forward 
trafficking to synaptic membrane271. Moreover, this mechanism is fostered by short-
term activation of the NMDAR in primary neurons269. However, NMDAR can also affect 
ADAM10 expression, because its activation leads to upregulation of the genes encoding 
ADAM10 and β-catenin proteins. Inhibitors of Wnt/β-catenin signaling abolished the 
ADAM10 upregulation, while the activation of the Wnt/ β-catenin signaling pathway by 
recombinant Wnt3A stimulated ADAM10 expression. Moreover, ERK inhibitors blocked 
both the NMDAR and Wnt3A-induced ADAM10 upregulation. These data suggest that 
the NMDA receptors control ADAM10 expression via a Wnt/ MAPK signaling 
pathway272. 
In addition, the ADAM10 cytoplasmic tail contains a ER retention motif that regulates 
its intracellular localisation. Indeed, sequential deletion/mutagenesis on this arginine-
rich sequence can alter the surface trafficking of the enzyme273. 
ADAM10 associates with different tetraspanins274. TSPAN12 is a partner of mature form 
of ADAM10 and promote the maturation of the protease275. Similarly, TSPAN15 also 
bound to ADAM10 in the ER. This complex was able to quickly pass through the 
secretory pathway, leading to more activated ADAM10 at the cell surface and increased 
ADAM10- mediated shedding events276. It is tempting to speculate that different 
TSPANs may modulate the cellular fate of ADAM10 (and other ADAMs), their 
substrates and also the function of the intramembrane cleaving proteases in a tightly 
coordinated fashion277.  
Another ADAM10 binding partner is the clathrin adaptor 2 (AP2), a heterotetrameric 
assembly that initiates the endocytosis process, interacts with an atypical AP2-binding 
motif (RQR) in ADAM10 C-terminal domain, and modifies its localisation. The LTP (long 
term potentiation) reduces the enzyme membrane levels by inducing AP2-mediated 
endocytosis271.  
 
1.4.4 ROLE OF ADAM10 IN ALZHEIMER’S DISEASE 
As regards ADAM10 involvement in AD pathogenesis, ADAM10 protein levels were 
found to be significantly reduced in platelets of sporadic AD patients and a significant 
decrease in sAPPα levels was detected in platelets and cerebrospinal fluid (CSF) of AD 
patients 278. In addition, it has been shown that α-secretase activity was reduced in 
temporal cortex homogenates from AD patients. In contrast, ADAM10 mRNA levels 
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were found to be two-fold increase in hippocampal and cerebellar sections of AD 
patients279. These results were obtained from the brains of severe AD patients and it is 
possible that, in later stages of the disease, ADAM10 expression is increased as a 
defense mechanism or as a secondary effect of inflammation and reactive gliosis. 
As mentioned above, the correct spatial localization of ADAM10 in the postsynaptic 
membrane is pivotal for an efficient APP α-secretase cleavage (Fig. 6), thus the 
mechanisms regulating the trafficking of ADAM10 play a key role in the modulation of 
its activity. We know that SAP97 and AP2 can modulate the localisation of ADAM10 
and thereby its activity. It has been shown that the ADAM10/SAP97 and ADAM10/AP2 
associations are involved in AD pathogenesis. Indeed, ADAM10 synaptic levels and 
ADAM10/SAP97 association are reduced in the hippocampus of AD patients in the early 
stage of the disease280. Interfering with the ADAM10/SAP97 complex for 2 weeks by 
means of a cell-permeable peptide strategy in mice is sufficient to increase amyloid 
levels and leads to the reproduction of initial phases of sporadic AD281. Specifically, 
there is a significant reduction in PKC mediated phosphorylation of SAP97 site in AD 
hippocampi when compared with age-matched control patients, that leads to a 
decrease of the SAP97/ADAM10 association270. 
ADAM10/AP2 association has also a pathological relevance; in fact, it has been 
demonstrated a concomitant increase in ADAM10 association to AP2 in the 
hippocampus of AD patients271. Our results suggest that in early stages of the disease, 
the reduction of α-secretase synaptic localization and activity could be ascribed to a 
defect in ADAM10 exocytosis/endocytosis processes rather than to an alteration of its 
expression. 
  
a soluble fragment, sAPPb, into the extracellular space. CTF99 can then be cleaved
by g-secretase at the C-terminus of Ab sequence; this processing allows the release
of the a yloidogenic Ab fragment and the amyloid intracellular domain (AICD)
(Fig. 25.1).
The cleavage of g-secretase releases Ab peptides of varying length from the
plasma membrane, depending on the site of cleavage. Of these, Ab42 has an
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Fig. 25.1 Scheme of the proteolytic events and cleavage products that are generated during the
processing of APP. APP is delivered to the surface membrane, where it is cleaved by a-secretase
within the sequence of Ab, thus precluding the formation of the amyloidogenic fragment. APP
molecules that fail to be cleaved by a-secretase can be internalized into endocytic compartments
and subsequently cleaved by b-secretase (BACE1) and g-secretase to generate Ab
576 E. Marcello et al.
E	Marcello	et	al.,	Journal	of	Cell	Science-2013		
Figure	6.	Amyloid	Cascade	
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1.4.5 ROLE OF ADAM10 IN OTHER CNS DISEASES 
ADAM10 has a role in several brain disorders, ranging from Huntington disease to 
mental retardation.  
For example, using conditional ADAM10 knockout mice (ADAM10 cKO or A10 cKO)258, 
it has been shown that the depletion of the protease in neural precursors leads to 
posttranslational accumulation of PrPC in the early secretory pathway282. Altmeppen 
and colleagues demonstrated that the lacking of ADAM10 leads to an increase level of 
PrPC, increased prion conversion and a reduced time in the incubation of prion disease. 
In light of these observations, it is clear the fundamental role of ADAM10 in the PrPC 
metabolism and in neurodegenerative events. 
Huntingtin is a large protein associated with the Huntington disease. The huntingtin 
protein (htt) inhibited ADAM10 activity and the shedding of its substrate N-cadherin, 
thus controlling neural adhesion during development. It is shown that the htt regulation 
of ADAM10 works through the modulation of the ADAM10-SAP97 complex 283.  
Interestingly, the majority of substrates of ADAM10 are either directly or indirectly 
involved in autism spectrum disorder (ASD), schizophrenia (SCZ) and bipolar disorder 
(BD), through both functional and genetic association284. For example, ADAM10 is also 
involved in the Fragile X syndrome, caused by mutations or deletions of the Fragile X 
mental retardation protein (FMRP). ADAM10 levels were found to depend on FMRP 
that controls the ADAM10 mRNA translation presumably by binding to the G-quadruplex 
structure in the 5-UTR of the ADAM10 mRNA285  
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2. AIM 
ADAM10 is one of the most important sheddase among the disintegrin and 
metalloproteinases family members. In neurons, ADAM10 is a component of the PSD, 
where it can act on many substrates, such as neuroligin-1, N-cadherin, NCAM and 
Ephrin. Thus ADAM10 has a crucial role in controlling synaptic adhesion molecules, 
spine morphology, and activity-dependent plasticity. Moreover, ADAM10 is the α-
secretase, the enzyme that cleaves APP within the Aβ domain, thus preventing Aβ 
generation. 
ADAM10 cleaves its substrate only when it is inserted at the plasma membrane and, 
therefore the intracellular trafficking of ADAM10 represents a mechanism capable of 
tuning its activity. In the last few years, the complex machinery responsible for ADAM10 
activity regulation in the synapses has been described. According to this, ADAM10 
forward trafficking to the synapse is mediated by SAP97. The phosphorylation of SAP97 
by PKC allows the trafficking of ADAM10 to the synapse from Golgi outposts, whereas 
the clathrin adaptor AP2 mediates the removal of ADAM10 from the plasma membrane. 
Both SAP97 and AP2 interact with the cytoplasmic tail of ADAM10. Therefore, the C-
terminal tail represents the locus responsible for the regulation of ADAM10 synaptic 
localization/activity. 
In light of these considerations, my PhD project aimed to identify new protein partners 
of ADAM10 Cterminal domain capable of modulating ADAM10 synaptic localization. 
We performed a yeast two-hybrid screening of a brain cDNA library using the ADAM10 
C-terminal tail as bait. Among the positive clones, we found a protein of particular 
interest, i.e. Cyclase-Associated Protein 2 (CAP2). CAPs are evolutionary highly 
conserved proteins involved in (i) processes orchestrating changes in actin 
cytoskeleton such as cell migration, movement and polarity, (ii) linking signalling 
pathways to elements of the cytoskeleton, (iii) vesicle trafficking and endocytosis1 
Hubberstey AV, Mottillo EP. Cyclase-associated proteins: CAPacity for linking signal 
transduction and actin polymerization 129 are essential for maintaining the balance 
between G- and F-actin. CAPs are highly conserved proteins that have been described 
in yeast, plants, Dictyostelium, Drosophila and mammals. CAP deficiency results in 
defects in vesicle trafficking, endocytosis, and in an altered cell morphology and cell 
growth 286. Two closely related homologs of CAP have been described in mammals. 
CAP1 is expressed in nearly all cells, whereas CAP2 expression is restricted to a limited 
number of tissues and is mainly found in brain, skin, skeletal and cardiac muscle 287. 
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Since at least one of the two CAP proteins is expressed in nearly all cells, it is likely that 
CAP1 and CAP2 complement each other in some cellular functions, but CAP2 may 
have unique roles, especially in neurons. 
 
Given that, the main goal of my phD project were to understand the functional role of 
ADAM10/CAP2 interaction. In particular, the specific aims were: 
1. to characterize CAP2 function in the brain, 
2. to investigate the capability of CAP2 to modulate actin dynamic, 
3. to determine CAP2 involvement in modulating ADAM10 synaptic localization 
4. to unravel CAP2 role in the remodelling of dendritic spines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 44	
3. MATERIALS AND METHODS 
 
3.1 ANIMALS  
Sprague–Dawley rats of 6 weeks, E18 embryos from Sprague–Dawley rats for primary 
hippocampal neuron cultures. All the experiments were approved by the OHSU 
Institutional Animal Care and Use Committee and by the Italian Health Ministry 
(#295/2012-A).  
 
3.2. Y2H SCREENING  
Y2H was conducted according to the manufacture’s procedure guidelines using the 
Mate & Plate Library—Mouse Brain (normalized; cat #630488, TakaraBio/Clontech 
Europe, France). Briefly, the ADAM10(697-748) C-tail (bait) was cloned in the pGBKT7 
plasmid and transformed in the AH109 haploid yeast strain (MATa). This was mated 
overnight with the Mouse Brain normalized library (prays) cloned in pGADT7 
transformed in Y187 haploid yeast strain (MATa). Yeast were plated after 24 h on 
selective plate, allowing only the growth of diploid where a protein interaction between 
the bait and pray protein occurred (absence of Leucine, Adenine, Tryptophan and 
Histidine). Then the diploids were tested by a colorimetric assay (a-gal) to avoid the 
presence of false positive. Plasmids (twenty-one positive clones) were extracted from 
the yeast and sequenced.  
 
3.3. PLASMIDS  
EGFP CAP2 plasmid was a kind gift from Professor Angelika Noegel (University of 
Cologne). This plasmid was used to perform point mutation inserting a stop codon for 
the codon corresponding to aa 452 using the QuikChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA), following the manufacturer's instructions.  
Myc CAP2 plasmid was created using the restriction enzyme and it was used to perform 
point mutation inserting a stop codon for the codon corresponding to aa 452, C32G 
using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA), 
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following the manufacturer's instructions. Myc CAP2 plasmid was used also to create 
the deletion mutant Myc CAP2 165-476 using the the restriction enzyme SalHI and NotI. 
Glutathione S-transferase (GST)-CAP2 fusion protein contains CAP2 sequence and the 
deletion mutant GST CAP2-452Δ the restriction enzyme BamHI-HF and XhoI. 
Glutathione S-transferase (GST)-ADAM10 C-terminal domain (Ct) fusion protein 
contains the cytoplasmic domain of ADAM10 (695–749)269. GFP was provided by Dr 
Maria Passafaro (CNR, Milan, Italy) 
 
3.4. CELL CULTURES AND TRANSFECTIONS 
COS7 cells were grown on 100 mm dishes and maintained in DMEM containing 
Glutamax (DMEM þ Glutamax, GIBCO) supplemented with 10% fetal bovine serum and 
penicillin–streptomycin (GIBCO). Cells were allowed to grow till confluence before 
passaging every 3–4 days using trypsin. The day before transfection, COS-7 cells were 
placed in a 12 wells multiwell (for imaging), then cells were transfected with 250–500 
ng of plasmid DNA using the lipofectamine LTX method (Invitrogen). After 36 h, COS-
7 cells were fixed for immunostaining/imaging. Hippocampal neuronal primary cultures 
were prepared from embryonic day 18–19 (E18-E19) rat hippocampi. Neurons were 
transfected at DIV10 using calcium-phosphate co-precipitation method with 2–4 µg of 
plasmid DNA. Neurons were treated at DIV15, fixed and then immunostained. 
 
3.5. FLUORESCENT IMMUNOCYTOCHEMISTRY 
Cells were fixed with 4% Paraformaldehyde (PFA)-4% sucrose in PBS solution at 4 °C 
and washed several times with PBS. Cells were either blocked with 5% BSA in PBS for 
30 min at room temperature and then labelled with primary antibodies for surface 
labelling for 1 h at room temperature or permeabilized with 0.1% Triton X-100 in PBS 
for 15 min at room temperature and then blocked with 5% BSA in PBS for 30 min at 
room temperature. Cells were then labelled with antibodies for intracellular epitopes for 
1 h overnight at 4 °C. Cells were washed and then incubated with secondary antibodies 
for 1 h at room temperature. Cells were then washed in PBS and mounted on glass 
slides with Fluoromount mounting medium (Sigma Aldrich) or permeabilized for total 
labelling.  
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3.6 SUBCELLULAR FRACTIONATIONS  
TIF, a fraction highly enriched in PSD proteins but absent of presynaptic markers63, 
was isolated from adult rat hippocampus. To this, samples were homogenized at 4 °C 
in an ice-cold buffer containing 0.32 M Sucrose, 1 mM HEPES, 1 mM NaF, 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM MgCl in the presence of protease inhibitors 
(Complete, GE Healthcare) and phosphatase inhibitors (PhosSTOP, Roche 
Diagnostics GmbH), using a glass- Teflon homogenizer. Homogenates were then 
centrifuged at 1,000g for 5 min at 4 °C, to remove nuclear contamination and white 
matter. The supernatant was collected and centrifuged at 13,000g for 15 min at 4 °C. 
The resulting pellet (P2 crude membrane fraction) was resuspended in hypotonic buffer 
(1 mM HEPES with Complete). Resuspended P2 were then centrifuged at 100,000g for 
1 h at 4 °C. Triton X-100 extraction of the resulting pellet was carried out at 4 °C for 20 
min in an extraction buffer (1% Triton X-100, 75 mM KCl and Complete). After 
extraction, the samples were centrifuged at 100,000g for 1 h at 4 °C and the TIFs 
obtained were resuspended in 20 mM HEPES with Complete.  
PSDs were isolated from rat hippocampus64. Rats (15 animals) were killed, hippocampi 
were dissected within 2 min and pooled. All hippocampi dissected in 42 min were 
discarded. Homogenization was carried out by 10 strokes in a glass-Teflon 
homogenizer (700 r.p.m.) in 4 ml/g of cold 0.32 M sucrose containing 1 mM HEPES, 1 
mM MgCl2, 1 mM NaHCO2 and 0.1 mM PMSF (pH 7.4). The homogenized tissue was 
centrifuged at 1,000g for 10 min. The resulting supernatant was centrifuged at 13,000g 
for 15 min to obtain a fraction containing mitochondria and synaptosomes. The pellet 
was resuspended in 2.4 µl/g of 0.32 M sucrose containing 1 mM HEPES, 1 mM 
NaHCO3 and 0.1 mM PMSF, overlaid on a sucrose gradient (0.85–1.0–1.2 M), and 
centrifuged at 82,500g for 2 h. The fraction between 1.0 and 1.2 M sucrose was 
removed, diluted with an equal volume of 1% Triton X-100 in 0.32 M sucrose containing 
1 mM HEPES, 15 min. This solution was spun down at 82,500g for 45 min. The pellet 
(Triton insoluble postsynaptic fraction, PSD1) was resuspended, layered on a sucrose 
gradient (1.0–1.5–2.1 M), and centrifuged at 100,000g at 4 °C for 2 h. The fraction 
between 1.5 and 2.1 M was removed and diluted with an equal volume of 1% Triton X-
100 and 150 mM KCl. PSD2 were finally collected by centrifugation at 100,000g at 4 °C 
for 45 min and stored at 80 °C until processing. All purifications were performed in the 
presence of complete sets of protease and phosphatase inhibitors (Roche Diagnostics). 
Protein content of the samples was quantified by using Bio-Rad protein assay.  
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3.7 TRITON INSOLUBLE SYNAPTIC MEMBRANE (TIF) 
To obtain the TIF fractions, samples of rat brain were homogenized at 4°C in an ice-
cold buffer with protease inhibitors (Complete™, GE Healthcare, Mannheim, Germany), 
Ser/Thr and Tyr phosphatase inhibitors (Sigma-Aldrich), 0.32 M Sucrose, 1 mM Hepes, 
1 mM NaF, 0.1 mM PMSF, 1 mM MgCl2 using a glass-teflon homogenizer. An aliquot 
of homogenate (Homo) was kept for Western Blot (WB) analysis. Homo were then 
centrifuged at 1000g for 5 min at 4°C, to remove nuclear contamination and white 
matter. The supernatant was collected and centrifuged at 13000g for 15 min at 4°C. 
The resulting pellet (crude membrane) was resuspended in resuspension buffer (1 mM 
Hepes with protease inhibitors (Complete™, GE Healthcare)) and then centrifuged at 
100000g for 1 h at 4°C. Triton-X extraction of the resulting pellet was carried out at 4°C 
for 20 min in an extraction buffer (1% Triton-X, 75 mM KCl and protease inhibitors 
(Complete™, GE Healthcare)). After extraction, the samples were centrifuged at 
100000g for 1 h at 4°C and the TIFs obtained were resuspended in 20 mM HEPES with 
protease inhibitors (Complete™, GE Healthcare). To get the soluble fraction (S2), 
samples of human brain were homogenized at 4°C in an ice-cold buffer with protease 
inhibitors (Complete™, GE Healthcare), Ser/Thr and Tyr phosphatase inhibitors 
(Sigma-Aldrich), 0.32 M Sucrose, 1 mM Hepes, 2 mM EDTA, 0.1 mM PMSF, 1 mM 
EGTA using a hand-held glass-teflon homogenizer. In this case, aliquots of Homo were 
kept to perform immunoprecipitation (ip) assay. Homo were then centrifuged at 1000g 
for 10 min at 4°C, to remove nuclear contamination and white matter. The supernatants 
were collected and centrifuged at 100000g for 1h at 4°C. The resulting pellet (crude 
membrane) was discarted and the supernatant obtained corresponds to the S2 fraction. 
 
3.8. CO-IP ASSAY 
A measure of 100 µg of proteins from rat hippocampus or HEK 293/COS 7 homogenate 
or 50 µg of proteins from rat hippocampus TIF were in RIA buffer containing 200 mM 
NaCl, 10 mM EDTA, 10 mM Na2HPO4, 0.5% NP-40, 0.1% SDS and protein A/G-
agarose beads as pre-cleaning procedure. Primary antibodies were added leaving to 
incubate overnight at 4 °C on a wheel. Protein A/G-agarose beads were added and 
incubation was continued for 2 h, at room temperature on a wheel. Beads were 
collected by gravity or centrifugation (1200 rpm) and washed three times with RIA buffer 
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before adding sample buffer for SDS–polyacrylamide gel electrophoresis (SDS–PAGE) 
and the mixture was boiled for 10 min. Beads were pelleted by centrifugation, all 
supernatants were applied onto 7–8% SDS–PAGE gels.  
 
3.9 PULL-DOWN ASSAY  
GST fusion proteins were expressed in Escherichia coli and purified on glutathione 
agarose beads (Sigma Aldrich). A measure of 200 µg of brain homogenate proteins 
were incubated with 40 ml of GST alone and with of GST fusion proteins of the C-
terminal domain of ADAM10 or GST CAP2-452Δ to a final volume of 1 ml in Tris-
Buffered Saline (TBS, 10 mM Tris and 150 mM NaCl) for 2 h on the rotator at room 
temperature. After incubation, beads were washed four times with TBS and 0.1% Triton 
X-100.  
 
3.10 NEURONAL CULTURE TREATMENT 
To induce chemical LTP, hippocampal neuronal cultures at 14 DIV were first incubated 
in artificial cerebrospinal fluid (ACSF) for 30 minutes: 125 mM NaCl, 2.5 mM KCl, 1 mM 
MgCl2, 2 mM CaCl2, 33 mM D-glucose, and 25 mM HEPES (pH 7.3; 320 mosM final), 
followed by stimulation with 50 μM forskolin, 0.1 μM rolipram, and 100 μM picrotoxin 
(Tocris) in ACSF (no MgCl2). After 16 minutes of stimulation, neurons were replaced in 
regular ACSF for 15 minutes and then subjected to TIF extraction or surface-expression 
assays288,289. TIF was isolated neurons as previously described 191.  
 
3.11 INTERNALIZATION ASSAYS 
To label surface TacADAM10-RAR, live COS7 cells were incubated with anti-Tac 
antibody for 45 minutes in medium at 4°C, while live neurons were labelled by 
incubation in ACSF with anti-Tac antibody for 30 minutes at 10°C. After brief washing 
in DMEM, COS7 cells were returned to 37°C for 10 minutes. Neurons were washed 
with cold ACSF, and internalization was allowed at 37°C in response to cLTP induction 
(16 minutes plus 15 minutes to allow internalization). A parallel set of controls was kept 
at 4–8°C to stop trafficking. Cells were then fixed with 4% PFA and 4% sucrose in PBS, 
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pH 7.4 and blocked with normal serum; remaining surface Tac chimeras were labeled 
with 488 secondary antibody (nonpermeabilized), and internalized receptors were 
labeled with 555-conjugated secondary antibody after Triton permeabilization. For 
COS7 internalization experiments, wide-field fluorescence images were acquired with 
a Zeiss ×40 objective and a CoolSnap CCD camera.  
 
3.12 FRAP EXPERIMENT 
Hippocampal neurons (DIV13) were transfected with GFP-Actin plus SH CAP2 or SCR 
as above. 48 hr later. After acquiring images from both channels, FRAP was performed 
only on the GFP-actin channel using the confocal LSM510 Meta system (Zeiss) with a 
63X objective. Prebleach fluorescent signal was acquired using a 488 nm line argon 
laser. A circular Region of Interest (ROI, 2 μm diameter) on a selected dendritic spine 
head was photobleached by scanning with the 488 nm argon laser line at 100% laser 
power with pixel dwell time of 2.2 μs, using acquisition settings of 256 × 256. 
 
3.13 ANTIBODIES 
The following primary antibodies were used: Ant-CAP2 (Santa Cruz Biotechnology 
1:100 WB and 1:200 ICC), Ant-CAP2 (Proteintech 1:1000 and 1:3000 WB and 1:100 
ICC), Anti-Actin (Sigma-Aldrich 1:10000 WB), Anti-Actin (Sigma-Aldrich 1:3000 WB), 
Anti-Tubulin (Sigma-Aldrich 1:20000 WB), Anti-Myc (9E10) (Roche 1:1000 WB and 
ICC), Anti-Myc (Santa Cruz Biotechnology 1:200 WB and 1:500 ICC), Anti-GFP 
(Synaptic System 1:500 WB), Anti-GFP (Millipore 1:500 ICC), Anti-GFP (Aves 1:1400 
ICC), Anti-Cofilin (Cell Signallin 1:1000 WB), Anti-MAP2 (Millipore 1:500 ICC), Anti-
GFAP (Cell Signalling 1:200 ICC), Anti-PSD-95 (Neuromab 1:300 ICC and 1:1000 WB), 
Anti-Bassoon (Neuromab 1:300 ICC), Anti-Synaptophisin (Synaptic System 1:1000 
WB) .The following secondary antibodies were used: goat anti-mouse-HRP (172–
1,011) and goat anti-rabbit-HRP (172–1,019, Bio-Rad), goat anti-mouse-Alexa488 (A-
11029), goat anti-mouse-Alexa555 (A-21422), goat anti-mouse-Alexa633 (A-21052), 
goat anti-rabbit-Alexa488 (A-11034) and goat anti-rabbit-Alexa555 (A-21429; Life 
Technologies). 
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4. RESULTS 
 
4.1 CAP2 IS A NOVEL BINDING PARTNER OF ADAM10 
To confirm the results of the two-hybrid screening, we carried out co-
immunoprecipitation assays from homogenates of rat hippocampus. As shown in Fig. 
1A, CAP2 is able to precipitate both ADAM10 and actin, but not ADAM22, another 
member of the ADAM family. No signal is detectable when the sample is precipitated 
without CAP2 antibody. Moreover, ADAM10 is not capable of precipitating CAP1, the 
protein homologous to CAP2, demonstrating the specificity of the complex 
ADAM10/CAP2. No signal is revealed when the sample is precipitated without ADAM10 
antibody or in samples without homogenate. 
These results were confirmed by colocalization analysis performed in COS7 cells 
transfected with ADAM10 and Myc CAP2. As shown in Fig. 1B, CAP2 expression 
modifies ADAM10 distribution pattern, enriching the enzyme in CAP2-clusters. 
Moreover, ADAM10 interaction with CAP2 was confirmed by proximity ligation assay 
(PLA). As shown in Fig. 1C, PLA signals were detected when the two antibodies 
recognizing ADAM10 and CAP2 were used, indicating that these two proteins are in 
close proximity (<40 nm) to each other. In order to identify the domain of ADAM10 
cytoplasmic tail recognized by CAP2 we carried out pulldown assays. Fusion proteins 
of glutathione-S-transferase (GST) and GST bound to ADAM10 C-terminal domain 
(GST- ADAM10 Ct) were incubated with rat hippocampus homogenate. GST- ADAM10 
Ct was able to specifically pull-down CAP2. Therefore, we tested a series of deletion 
mutants of GST-ADAM10 Ct, to identify the domain of ADAM10 responsible for the 
interaction with CAP2 (Fig. 1D). Truncation of the last 41 aa of ADAM10 tail (GST-708Δ) 
abolished binding to CAP2 (Fig. 1E), indicating that the ADAM10 most membrane 
proximal Pro Rich region is required for the interaction with CAP2.  
On the other hand, we generated different deletion mutants of EGFP-CAP2 to define 
the CAP2 domain required for its interaction with ADAM10 (Fig. 1F). We deleted the 
last 22 aa (452Δ), the C-terminal domain and the Pro-rich region 2 (311Δ), the Pro-rich 
regions (232Δ) 
HEK 293 cells stably transfected with ADAM10-HA were transfected with either EGFP 
CAP2 or EGFP CAP2 452Δ or EGFP CAP2 311Δ, or EGFP CAP2 232Δ. The cells 
extracts were immunoprecipitated with the HA antibody and the immunocomplex 
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probed for EGFP. Fig. 1G shows that the first 232 amino acids of CAP2 contains the 
ADAM10-binding site, revealing that ADAM10 interacts with the N-terminal part of 
CAP2. All together these data demonstrate that CAP2 is a novel protein partner of 
ADAM10 in neuronal cells, since CAP2 N-terminal domain is able to interact with 
ADAM10 most membrane-proximal sequence in its cytoplasmic domain. 
 
Figure 1. CAP2 is localized in the postsynaptic compartment but it is not enriched in the PSD. 
A. Expression of ADAM10, CAP2, Actin in brain areas: HIPPO hippocampus, STR striatum, CTX cortex, 
CRB cerebellum. Tubulin was used as internal control. 
B. Time course of expression of ADAM10, CAP2, Actin in brain homogenate of rats at E9, P7, P14 and 
P21   (E = embryonic day, P = post-natal). Tubulin was used as control. 
C. Time course of expression of ADAM10, CAP2, Actin in hippocampal neurons at DIV6, 8, 10, 13, 15 
(DIV= day in vitro). Tubulin was used as control. 
D. Immunocytochemistry of CAP2, MAP2(neuronal marker) and endogenous GFAP (astrocytes marker). 
E. Post-synaptic density purified from adult rat hippocampi, CAP2 is present all the fractions but not 
enriched in PSD as ADAM10. Legend: Homo, Homogenate; S1, Supernatant 1; P1, Pellet 1; S2, 
Supernatant 2; P2, Pellet 2; S3, Supernatant fraction; P3, microsomal fraction; PSD1; PSD2, post-
synaptic density. 
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F. Representative staining of CAP2 and synaptic markers. After fixation, neurons were stained with post 
and pre synaptic markers, PSD-95 and Bassoon respectively, to evaluate the localisation of CAP2 at the 
synapse. 
G. Immunocytochemistry of CAP2, phalloidin (F-actin marker) and endogenous PSD-95 in DIV15 primary 
hippocampal neurons. 
 
4.2 CAP2 localization in the brain 
Since a careful characterization of CAP2 function in the brain is still missing (Kumar et 
al., 2016), first we determined CAP2 expression profile in different brain areas and 
CAP2 localization at a subcellular level. Western Blot analyses revealed similar CAP2 
protein levels in cortex, hippocampus, striatum and cerebellum. The analysis of CAP2 
expression during development showed an increase from postnatal day 14 and, in 
hippocampal neuronal culture, from day in vitro 8 (Fig. 2A, B, C).  
Immunostaining assays performed with a CAP2 antibody and markers for neuronal cells 
(MAP2) and astrocytes, as GFAP, demonstrated that CAP2 is expressed in both cells 
(Fig. 2D). To investigate CAP2 subcellular localization we took advantage of a 
biochemical fractionation approach to isolate excitatory PSDs from rat hippocampus. 
We found that CAP2 is present in all the fractions but is not enriched in the PSD, as 
ADAM10 (Fig. 2E). Focusing on the synaptic localisation of the protein, confocal 
analyses revealed that CAP2 co-localizes with PSD-95, a post-synaptic marker, but not 
with Bassoon, a presynaptic protein (Fig. 2F). Moreover, CAP2 showed a partial 
colocalization with the postsynaptic protein PSD- 95, while it perfectly colocalizes with 
phalloidin, a marker for F-actin, suggesting that CAP2 is localized in the region close to 
the PSD, where the actin cytoskeleton is present (Fig. 2G).  
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Figure 2. CAP2 is localized in the postsynaptic compartment but it is not enriched in the PSD. 
A. Expression of ADAM10, CAP2, Actin in brain areas: HIPPO hippocampus, STR striatum, CTX cortex, 
CRB cerebellum. Tubulin was used as internal control. 
B. Time course of expression of ADAM10, CAP2, Actin in brain homogenate of rats at E9, P7, P14 and 
P21   (E = embryonic day, P = post-natal). Tubulin was used as control. 
C. Time course of expression of ADAM10, CAP2, Actin in hippocampal neurons at DIV6, 8, 10, 13, 15 
(DIV= day in vitro). Tubulin was used as control. 
D. Immunocytochemistry of CAP2, MAP2(neuronal marker) and endogenous GFAP (astrocytes marker). 
E. Post-synaptic density purified from adult rat hippocampi, CAP2 is present all the fractions but not 
enriched in PSD as ADAM10. Legend: Homo, Homogenate; S1, Supernatant 1; P1, Pellet 1; S2, 
Supernatant 2; P2, Pellet 2; S3, Supernatant fraction; P3, microsomal fraction; PSD1; PSD2, post-
synaptic density. 
F. Representative staining of CAP2 and synaptic markers. After fixation, neurons were stained with post 
and pre synaptic markers, PSD-95 and Bassoon respectively, to evaluate the localisation of CAP2 at the 
synapse. 
G. Immunocytochemistry of CAP2, phalloidin (F-actin marker) and endogenous PSD-95 in DIV15 primary 
hippocampal neurons. 
 
4.3 CAP2 FORMS DIMERS 
Since CAP2 staining appears punctuate (Fig. 1D) and it has been reported that the 
dimerization is an important characteristic of CAP1 (Hubberstey et al., 1996), we 
hypothesized that also CAP2 could form dimers. First of all, to test this hypothesis COS 
7 cells were co-transfected with Myc CAP2 and EGFP CAP2. As shown in Fig. 3A, Myc 
CAP2 and EGFP CAP2 perfectly colocalize in perinuclear clusters. In addition, we 
performed immoprecipitation assays from the lysates of COS-7 cells transfected with 
Myc CAP2 and EGFP CAP2. The precipitation of Myc CAP2 implicates the co-
precipitation of EGFP-CAP2, suggesting that CAP2 can associate in aggregates. 
In order to identify the domain responsible for the self-association, we took advantage 
several deletion mutants of EGFP CAP2 (Fig. 1F) to performed a co-
immunoprecipitation assays from lysates of COS 7 cells transfected with Myc CAP2 full 
length and the deletion mutants of EGFP CAP2. We found out that the deletion of the 
Proline rich regions of CAP2 and the WH2 domain did not interfere with the dimer 
formation, since the presence of the N-terminal (1-232 aa) was sufficient for the 
interaction with CAP2 full length (Fig. 3B). To narrow down the region responsible for 
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the dimerization we collaborated with Dr. Di Marino (University of Lugano), who carried 
out a computational analysis that predicted the first N-terminal 165 aa as the 
dimerization region (Fig. 3C).  
We generated the mutant Myc CAP2 165-476, lacking of the predicted dimerization 
domain.  When transfected in COS7 cells, Myc CAP2 165-476 displayed a diffuse 
pattern through the cell and no clusters were detected as in cells expressing Myc CAP2 
FL and Myc CAP2 232 Δ (Fig. 3D).  
To verify the presence of the dimer in physiological conditions, we loaded samples of 
total homogenate and Triton-Insoluble Fraction (TIF), which is enriched in postsynaptic 
proteins, onto a native-like condition gel. We detected a band corresponding to CAP2 
monomer (53 kDa) and a band with an apparent molecular weight of 106 kDa that could 
correspond to a CAP2 dimer (Fig. 3E). Interestingly, the CAP2 dimer is enriched in the 
the TIF when compared with the total homogenate.  
The CAP2 monomer and dimer are also detectable when we load lysates of Myc CAP2-
transfected HEK293 cell onto a native-like. However, when we load homogenate of 
cells expressing the mutant Myc CAP2 165-476, lacking of the N-terminal domain, the 
band with an apparent molecular weight of 106 kDa is not revealed. Since the detection 
of such 106 kDa band depends on β-mecaptoethanol presence in the loading buffer we 
hypothesized that a disulfide bond could be responsible for the dimer formation. In the 
domain 1-165 aa there is only the cysteine 32, thus suggesting that this aa can be 
relevant for the dimerization. In fact, when we load the extracts of cells transfected with 
the mutant of MycCAP2 carrying the single point mutation 32C to G onto a native-like 
gel, the band at 106 kDa is not detectable (Fig. 3F).  
However, both Myc CAP2 C32 to G and Myc CAP2 165-476 were able to co-precipitate 
with EGFP CAP2 full length, suggesting that the Cysteine 32 is not the only residue 
responsible for CAP2 self-association (Fig. 3G). Indeed, it has been shown that there 
are at least two binding sites within CAP that mediate its dimerization (Hubberstey et 
al., 2002). Hubberstey and colleagues reported that the amino-terminal domain of 
human CAP (aa 1–228) interacts with itself as well as with the carboxyl-terminal domain 
(amino acids 253–475). Likewise, the C-terminal domain of CAP2 interacts with itself 
and with the N-terminal region through different types of chemical bonds. Moreover, it 
is still unclear in the literature whether CAP proteins form dimers or higher order 
structures, with several possibilities, such as C-C or C-N or N-N binding (Hubberstey et 
al., 2002).  
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Finally, we verified whether the mutant Myc CAP2 C32 to G is still able to bind ADAM10. 
We performed coimmunoprecipitation assay in HEK 293 stably transfected with HA 
ADAM10 and transfected with either Myc CAP2 full-length or the mutant Myc CAP2 
C32 to G. As shown in Fig. 2H, the mutant Myc CAP2 C32 to G is still able to bind 
ADAM10, demonstrating that such residue is not important for ADAM10/CAP2 
association.	
 
 
Figure 3. CAP2 is able to self-associate and forms dimers and cluster-like structures. 
A. COS-7 cells transfected with Myc CAP2 and EGFP-CAP2 and stained with anti GFP and anti Myc 
antibodies; the analysis reveals that Myc CAP2 and EGFP-CAP2 colocalize in clusters.  
B. Co-IP assays carried out from homogenate of HEK293 cells transfected with Myc CAP2 and different 
deletion mutants of EGFPCAP2. The sequence 1-232 of CAP2 is sufficient for CAP2 self-association. 
C. Molecular modelling of N-terminal part of Cap of Dictyostelium. 
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D. Representative scheme of the different CAP2 mutant constructs transfected in COS7 cells. Confocal 
imaging of COS7 cells co-transfected with Myc CAP2 , Myc CAP2 232Δ and Myc CAP2 165-476 shows 
that the region 1-232 is sufficient for clusters formation while the deletion of the sequence 1-165 
completely abolishes the presence of clusters . 
E. Samples of rat brain homogenate and TIF were loaded onto a non-denaturating gel. Western blot 
analysis performed with CAP2 antibody showed a band corresponding to CAP2 (53 KDa) and another 
band at 106 KDa corresponding to a CAP2 dimer. 
F. Homogenates of cells expressing different mutants of CAP2 were loaded onto a non-denaturating gel; 
WB analysis was performed with Myc antibody and revealed the different capability of the mutants to 
dimerize. The single point mutation 32C to G avoid the capability to form dimers onto a native-like 
condition gel. 
G. Co-IP assays carried out from homogenate of HEK293 cells transfected with EGFP CAP2 and either  
Myc CAP2 C32 to G or Myc CAP2 165-476. The results show that this mutants are still able to interact 
with EGFP-CAP2. 
H. Co-IP assays carried out from homogenate of HEK293 cells stable transfected with ADAM10-HA and 
Myc CAP2 C32 to G to evaluate its capability to bind ADAM10. This mutant is still able to associate to 
ADAM10. 
	
 
4.4 CAPABILITY OF CAP2 TO MODULATE ACTIN DYNAMIC 
CAP2 plays an important role in regulating the actin cytoskeleton and in signal 
transduction. It has been reported that in cardiomyocytes and keratinocytes, CAP2 is 
essential for normal actin organization because of the binding to G-actin, which 
regulates actin filament dynamics (Peche V.et al., 2007).  
To verify it, we took advantage of COS7 cells as a quick and easy tool to analyse the 
actin dynamics. We transfected COS7 cells with Myc CAP2 and stained G-actin with 
DnaseI and F-actin with phalloidin. CAP2 full length colocalized with the monomeric 
actin but not with filamentous actin. The statistical analysis showed a significant 
increase in the G-actin/F-actin ratio in cells transfected with Myc CAP2 when compared 
to mock cells, suggesting that CAP2 mediates actin depolymerisation in COS7 cells 
(Fig. 4A). Moreover, we noticed that the actin dynamics was influenced by the 
aggregation status of CAP2.  
We could recognize a population of cells in which CAP2 formed a single perinuclear 
structure (named polymeric structure) and other cells in which CAP2 was organized in 
small clusters scattered in the cytoplasm (called oligomeric structure). Interestingly, the 
G-actin/F-actin ratio was significantly higher in cells in which CAP2 was present as 
polymeric structure than in cells with CAP2 oligomeric structures, suggesting that CAP2 
aggregation is important for actin dynamics. (Fig. 4B).  
The next step was to investigate CAP2 directly in neurons. Immunostaining analyses 
revealed that CAP2 colocalized with F-actin. Indeed, CAP2/F-actin colocalization 
degree is significantly reduced by latrunculinA, a drug able to block actin polymerization, 
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thus indicating that CAP2 binds filamentous actin in neurons (Fig. 4C). Furthermore, we 
set up a biochemical assay to separate G-actin and F-actin.  The results obtained 
confirmed the data of the immunostaining: CAP2 is enriched in the F-actin fraction. 
Moreover, we validated this assay by analysing the distribution of G-actin binding 
proteins, such as phosphorylated Cofilin, that is enriched in G-actin fraction, as 
expected (Fig. 4D).  
Despite these unexpected results showing that CAP2 bids F-Actin and not G-actin in 
neuronal cells, we investigated the CAP2 role in actin polymerisation and we found out 
that CAP2 can mediate the depolymerisation of actin, since the overexpression of Myc 
CAP2 in neuronal cells leads to an increase in G-actin/F-actin ratio (Fig. 4E). According 
to these results, the transfection of CAP2 shRNA resulted in a decrease in G-actin/F-
actin, indicating a shift towards F-actin (Fig. 4F). 
The literature shows the complex role of CAP protein in actin dynamics. Indeed, several 
studies showed that CAP sequesters actin monomers, but also that CAP enhances the 
recharging of actin monomers promoting the severing of actin filaments in cooperation 
with ADF/cofilin. To clarify the mechanism by which CAP2 can modulate the actin 
dynamics in spines, we took advantage of fluorescence recovery after photobleaching 
(FRAP) experiments carried out in a single spine of hippocampal neuronal cells 
transfected with GFP actin, that was partially incorporated into the actin filaments, and 
either CAP2 shRNA or its scrambled control sequence (Koskinen et al,. 2012).  
Actin filaments in spines normally turn over rapidly, due to treadmilling, while actin 
monomers exchange bidirectionally between spines and the adjacent dendritic shaft. If 
GFP-actin in a spine is photobleached, new fluorescent GFP-actin monomers normally 
diffuse into the spine and are incorporated into the barbed end of bleached filaments, 
predominantly in the juxtamembrane (‘shell’) region of the spine head (Hotulainen et 
al., 2009; Frost et al., 2010). Concomitantly, bleached actin molecules are severed from 
filament pointed ends (closer to the spine ‘core’) and exchange out of the spine, which 
recovers its fluorescence. 
However, if turnover is impaired, bleached GFP-actin remains trapped within filaments 
and FRAP is attenuated. The fraction of actin filaments in the spine that are undergoing 
rapid turnover can thus be determined from the extent of FRAP (Star et al., 2002). 
The recovery of GFP-actin fluorescence, after the spine photobleaching, in CAP2 
knockdown neurons was significantly increased, compared to control neurons, 
indicating that is consistent with a significant decrease in the percentage of stable GFP-
	 58	
actin in spines lacking of CAP2. In contrast to these marked effects on the pool of stable 
actin, the half-time of GFP-actin fluorescence recovery was not significantly different 
(Fig. 4G). Taken together, these data suggest that the predominant effect of loss of 
CAP2 on GFP-actin turnover is to increase the pool of mobile actin in spines, promoting 
the treadmilling of actin, thus leading to a faster rate of actin turnover.  
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Figure 4. CAP2 affects actin dynamics in neurons and specifically in the spine.  
A. COS 7 cells transfected with Myc CAP2 FL to evaluate the capability influence the polymerisation of 
actin. The ratio G-actin/Factin has been calculated by measuring the integrated density of DNAse (G-
actin marker) and Phalloidin (F-actin marker) staining. Data are presented as mean ± s.e.m., n = 33–38, 
***P< 0.001, unpaired Student’s t-test.  
B. G-actin/F-actin ratio was calculated in COS 7 cells transfected with Myc CAP2 FL presenting CAP2 
as a single perinuclear structur(polymeric) e and in cells were CAP2 was aggregated in cluster localized 
in the cytoplasm (oligomeric). The capability of CAP2 to influence the G/F ratio is link to it’s structure 
(oligomeric or polymeric structure). Data are presented as mean ± s.e.m., n = 17-15, *P< 0.05, unpaired 
Student’s t-test.  
C. Hippocampal neurons were treated with latrunculin A to evaluate the capability of CAP2 to bind F-
actin. Immunostaining for CAP2 and F-actin (phalloidin) revealed that CAP2 colocalizes with F-actin, 
whereas the treatment with latrunculin A reduces the percentage of colocalisation. Data are presented 
as mean ± s.e.m., n = 17–15, *P< 0.05, unpaired Student’s t-test.  
D. Immunoblots of G-actin (G) and F-actin (F) fractions obtained from hippocampal neurons taking 
advantage of an Actin Polymerization Assay kit. CAP2 is present in the F-actin pellet, while Phospho 
Cofilin is present in the supernatant and Cofilin in both fraction, as expected. 
E. Hippocampal neuron were transfected with Myc CAP2 to evaluate the capability of influencing the 
polymerisation of actin. As in COS-7 cells, CAP2 overexpression increases the G-actin/F-actin ratio. Data 
are presented as mean ± s.e.m., n = 19–29, ***P< 0.001, unpaired Student’s t-test.  
F. Hippocampal neuron were transfected with either SH CAP2 or the scrambled control sequence (SCR) 
and G-actin/F-actin ratio was assessed. The loss of CAp2 significantly decreases the G-actin/F-actin 
ratio. Data are presented as mean ± s.e.m., n = 22–22, *P< 0.05, unpaired Student’s t-test.  
G. The rate of actin turnover was analysed by FRAP in hippocampal neuron transfected with GFP actin 
and either SH CAP2 or SCR at DIV 11. The FRAP analysis was performed at DIV 13. FRAP curves 
(normalized to average pre-bleach 
fluorescence), plotted from multiple single-spine ROIs for each condition. Histogram of the stable fraction 
of GFP-actin (mean ± SEM) calculated for each individual FRAP trace used to generate the pooled data 
 
Since it was clear that CAP2 affects the actin dynamic, the next step was to identify the 
actin binding region in CAP2 sequence. First we demonstrated that CAP2 can associate 
with both actin and cofilin performing a coimmunoprecipitation assay from rat brain 
homogenate (Fig. 5A).   
Then, we generated the fusion protein GST-CAP2 linking the GST to either CAP2 full-
length or the deletion mutant GST-CAP2-452Δ lacking of the CAP2 C-terminal domain 
that has been reported to bind actin. Pull-down assays revealed that the GST-CAP2 
452Δ mutant is not able to interact with actin, thus demonstrating that the last 22 aa of 
CAP2 are essential for actin binding (Fig. 5B). We confirmed these results carrying out 
a coimmunoprecipitation assay from the lysate of COS7 cells transfected with Myc 
CAP2 452Δ. This deletion mutant could not bind actin, but it is still able to interact with 
cofilin. In addition, we tested the binding capability of the Myc CAP2 C32 to G mutant 
and we verified that it can associate to both actin and cofilin (Fig. 5C). Moreover, when 
we loaded lysates of cells expressing the mutant Myc CAP2 452Δ onto a native-like gel, 
the 106 kDa band was detectable, suggesting that the lack of the last 22 aa does not 
affect CAP2 Cys32-dependent dimerization (Fig. 5D). 
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To unravel the effect of the loss of CAP2 actin binding domain on actin dynamics, we 
transfected either Myc CAP2 or Myc CAP2 452Δ in COS 7 cells and in hippocampal 
neurons. Surprisingly, the lack of the actin binding domain didn't revert the effect of 
CAP2 on the G-actin /F-actin ratio both in COS7 cells and in hippocampal neurons (Fig. 
5E, F), indicating that this C-terminal domain is not important for the polymerization of 
actin.		
	
 
	 61	
Figure 5. The actin binding domain of CAP2 is not relevant for the modulation of actin dynamics.  
A. Rat brain homogenate was immunoprecipitated (IP) with CAP2 antibody and WB analysis was carried 
out with an anti actin and cofilin antibody. CAP2 specifically interacts with both actin and cofilin. 
B. Actin interacts with the C-terminal tail of CAP2. GST CAP2 FL– full length, GST CAP2 Δ452 –(1-452) 
were incubated in a pull-down assay with rat brain homogenate.  WB analysis was performed with ACTIN 
antibody. GST proteins were stained by Coomassie staining. The deletion of the last 24 amminoacids 
abolishes actin binding to CAP2, suggesting that this is the sequence responsible for the interaction. 
C. Co-IP assays carried out from homogenate of HEK293 cells transfected with different mutants of Myc 
CAP2 to evaluate their capability to bind actin and cofilin.  
D. The mutant Myc CAP2 Δ452 is able to create dimers, as shown by the presence of the band at 106 
kDa in native-like gels. 
E. COS 7 cells were transfected with Myc CAP2 FL and Myc CAP2 Δ452 to evaluate the capability of 
influencing the polymerisation of actin. Myc CAP2 induces the depolymerisation of actin, and the lack of 
the actin binding domain does not affect this property. Data are presented as mean±s.e.m., n= 33-38, 
***P<0.001; n= 33-38, *P<0.05; one-way ANOVA followed by Bonferroni post-hoc test.  
E. Hippocampal neuron were transfected with Myc CAP2 to evaluate the capability of influencing the 
polymerisation of actin. As in COS7 cells, CAP2 overexpression increases G-actin/F-actin ratio and the 
lack of the last 24 aa does not influence this effect, Data are presented as mean±s.e.m., n= 19;29; 
**P<0.005; one-way ANOVA followed by Bonferroni post-hoc test.  
 
4.5 CAP2 ACTIVITY ON ADAM10 LOCALIZATION 
Given the importance of the CAP family in protein trafficking and endocytosis, we 
evaluated that if CAP2 and, in particular, its actin binding domain played a relevant role 
in ADAM10 membrane localization. First, we performed coimmunoprecipitation 
experiments from the homogenate of ADAM10-HA stable transfected HEK293 cells 
transfected with either EGFP-CAP2 or EGFP CAP2 452Δ. As shown in Fig. 6A, we 
confirmed that EGFP CAP2 452Δ can't bind actin but it is still able to associate to 
ADAM10, indicating that ADAM10 and actin binding region did not overlap in CAP2. 
Thus, we decided to evaluate the membrane localization of ADAM10 in COS7 cells 
transfected with ADAM10 and either with CAP2 full length (CAP2 FL) or the mutant 
lacking of the actin binding domain (CAP2 452Δ). The quantitative analysis showed that 
the mutant lacking of the actin binding domain significantly increases the surface 
localization of ADAM10 while the CAP2 FL didn’t affect the membrane level of the 
protein (Fig. 6B). We confirmed this result in neuronal cells where the co-localization 
between ADAM10 and PSD-95 increased in neuron transfected with the mutant CAP2 
452Δ while, again, the CAP2 FL didn’t modulate the synaptic localization of ADAM10 
(Fig. 6C). 
Since the actin binding site of CAP2 affects the levels of surface level of ADAM10, we 
investigated which mechanism is responsible for the modulation of this process. We 
decided to evaluate two pathways that are fundamental for ADAM10 localization: the 
forward trafficking and the endocytic process of the protein (Marcello et al., 2013). First, 
we performed an internalization assay in COS7 cells transfected with TacADAM10-RAR 
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and either Myc CAP2 full length or the mutant Myc CAP2 452Δ. The mutant of CAP2 
significantly impaired the endocytosis rate of ADAM10 while CAP2 full length didn't 
modulate ADAM10 internalization (Fig. 6D). The actin cytoskeleton plays an essential 
role in endocytosis. Actin assembly can create protrusions that encompass extracellular 
materials. Actin can also support the processes of invagination of a membrane segment 
into the cytoplasm, elongation of the invagination, scission of the new vesicle from the 
plasma membrane, and movement of the vesicle away from the membrane (Mooren et 
al., 2012). Therefore, these data suggest that CAP2 is involved in ADAM10 
endocytosis, probably anchoring the protein to the actin cytoskeleton. 
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Figure 6. CAP2 actin binding domain impairs ADAM10 endocytosis. 
A. Co-ip assay revealed the capability of CAP2 452D to bind ADAM10, even if it can’t bind actin. 
B. COS-7 cells were cotransfected with ADAM10 and either Myc CAP2 or the mutant Myc CAP2 Δ452, 
the mutant lacking of the actin binding domain. The expression of Δ452 significantly increases ADAM10 
membrane localisation. Data are presented as mean±s.e.m., n= 16;13; *P<0.05; one-way ANOVA 
followed by Bonferroni post-hoc test.  
C. Hippocampal neurons cotransfected with GFP, EGFPCAP2, or EGFPCAP2 Δ452. Cells were fixed, 
and stained for endogenous ADAM10 and PSD-95. The transefection of CAP2 does not affect ADAM10 
synaptic localisation, while the expression of the mutant Δ452 significantly increases ADAM10 
colocalisation with PSD-95. Data are presented as mean±s.e.m., n= 43;21; ***P<0.001; n= 46;21; 
**P<0.005; one-way ANOVA followed by Bonferroni post-hoc test.  
D. Antibody uptake assays were performed on COS7 cells transfected with either TacADAM10-RAR 
and Myc-CAP2 or with the mutant Myc-CAP2 Δ452. Representative images of cells returned to 37°C to 
allow endocytosis. The expression of the mutant lacking of the actin-binding domain significantly 
impairs ADAM10 endocytosis. Data are presented as mean±s.e.m., n= 11;11; *P<0.05; one-way 
ANOVA followed by Bonferroni post-hoc test.  
	
	
4.6 ADAM10/CAP2 COMPLEX IN SPINE REMODELLING 
We hypothesized that CAP2 could affect spine morphology, since modulates actin pools 
in the spines, as demonstrated by FRAP experiments (see Fig. 3G), and can influence 
ADAM10 localization and, thereby, its synaptic activity. Indeed, ADAM10 is important 
for the spine morphology because works as sheddase towards a number of neuronal 
adhesion molecules.  
To test this hypothesis, first we transfected hippocampal neuronal cells with CAP2 
shRNA and the corresponding control. Our analysis revealed that there was no 
significant difference in the neck width, the head width and the density of spines, 
whereas we detected a significant difference in the length of the spines, suggesting that 
CAP2 is involved in the remodelling of the spine shape, which is deeply linked to the 
actin polymerization (Fig. 7A). The morphology of hippocampal neurons was also 
analysed by tracing the dendrites of neurons transfected with GFP and either CAP2 
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shRNA or the scrambled control sequence and we found out that the absence of CAP2 
reduce the complexity of dendrites branching (Fig. 7B). We analysed the spine 
morphology also in neurons overexpressing either CAP2 full length or the mutant CAP2 
452Δ. We used the GFP to fill the neuron and we noticed that CAP2 full length 
overexpression increased the spine head width, without affecting spine length and 
spines density. Notably, this effect was reverted by the lack of the last 22AA in the 
mutant CAP2 452Δ, thus suggesting that the actin binding site of CAP2 is essential for 
the spine remodelling related to CAP2 (Fig. 7C). We have shown that this actin binding 
site in CAP2 is not involved in the regulation of actin dynamics but has a role in the 
control of ADAM10 membrane levels. Therefore, the lack of the last 22 influence spine 
shape because it impairs ADAM10 endocytosis, thus increasing its synaptic levels and 
thereby its shedding activity towards neuronal adhesion molecules.  
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Figure 7. CAP2 modulates spine morphology. 
E. The overexpression of CAP2 in hippocampal cultures significantly increases the width of dendritic 
spines without changing the length and the density; while the mutant 452D doesn’t affect significantly the 
width parameter. Data are presented as mean±s.e.m., n= 10;10; **P<0.005; n= 10;10; ***P<0.001; one-
way ANOVA followed by Bonferroni post-hoc test.  
F. The silencing of CAP2 leads to a significant increase of the spine length. Data are presented as mean 
± s.e.m., n = 7-7, *P< 0.05, unpaired Student’s t-test.  
G. Representative images of hippocampal neurons transfected with GFP and cotransfected with either 
SHCAP2 or SCR. Sholl analysis shows a decrease in dendrite branching in neurons lacking of CAP2 
 
The importance of ADAM10 in spine remodelling is demonstrated by the synaptic 
plasticity-dependent modulation of ADAM10 synaptic localization/activity. It has been 
reported that LTD promotes ADAM10 synaptic membrane insertion and stimulated its 
activity. ADAM10 interaction with SAP97 is necessary for LTD-induced ADAM10 
trafficking and required for LTD maintenance and LTD-induced changes in spine 
morphology. While in hippocampal neuronal cultures LTP induces ADAM10 
endocytosis through AP2 association and decreases synaptic ADAM10 levels and 
activity (Marcello et al., 2013). 
Therefore, we wondered whether activity-dependent synaptic plasticity modulates also 
CAP2 synaptic availability in the dendritic spines. To test this hypothesis, we induced 
chemical LTP (cLTP), using a highly validated protocol, in hippocampal cultures 
(Marcello et al, 2013). To induce LTP, we used a chemical stimulation protocol with 
forskolin plus rolipram for 16 minutes that results in prolonged NMDA receptor-
dependent LTP (cLTP). 15 min after cLTP induction, TIF was purified from control and 
cLTP-treated hippocampal neurons, and TIF samples were loaded onto a native-like 
gel to reveal CAP2 monomer and dimer.  cLTP stimulation caused a significant increase 
in CAP2 dimer levels in TIF (Fig. 8A). We analysed also the interaction of CAP2 and 
actin and coimmunoprecipitation assays demonstrated a significant decrease in the 
association between CAP2 and actin (Fig. 8B). Taken together these data demonstrate 
that LTP can modulate CAP2 properties promoting the C32-dependent dimerization in 
the synapses and inducing actin detachment from CAP2. 
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Figure 8. cLTP can modulate CAP2 properties.  
A. Tif purification of control and cLTP-treated neurons. cLTP (15’) promotes CAP2 dimerization in the 
TIF fraction. The ratio dimer/ monomeris expressed as percentage of control. Data are presented as 
mean ± s.e.m., n = 8, *P< 0.05, paired Student’s t-test.  
B. CAP2/Actin co-IP assays performed on tif of control and cLTP-treated neurons. cLTP (15’) abolishes 
CAP2/Actin binding in the TIF fraction.  
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5. CONCLUSION 
Several studies highlighted the key role of the disintegrin and metalloproteinase family 
member ADAM10 in health and disease, due to its shedding activity toward a number 
of functional membrane proteins such as APP and N-cadherin 271 
The proteins at the surface of cells play important functions for the cell-cell 
communication, intracellular signalling and they can control the synapse remodelling. 
The control of the cell surface protein indirectly regulates the shape of the spines and 
thereby their functionality. Indeed, spines undergo dynamic changes in their 
morphology, and this structural modifications correlate with the alterations in synaptic 
strength228. Therefore, ADAM10 activity can control the synaptic function through the 
cleavage of its substrates. On the other hand, ADAM10 undergoes a dynamic regulation 
of its activity by synaptic plasticity, that modulates its localisation. The synaptic 
localisation is crucial for ADAM10 synaptic activity because ADAM10 can act on its 
substrate only when it is inserted in the plasma membrane. Indeed, LTD promotes 
ADAM10 membrane insertion through the association with SAP97, whereas LTP 
reduces the enzyme membrane levels by inducing AP2-mediated endocytosis. In light 
of the above, ADAM10 delivery to the postsynaptic compartment seems to be critical 
for synaptic activity–induced spine remodelling. In fact, ADAM10 cleavage of synaptic 
adhesion molecules may allow the activated synapse to rapidly modulate the spine size 
during induction of activity-dependent synaptic plasticity 271. 
Given the importance in the localisation of ADAM10 at the cell surface, the trafficking 
of the enzyme assumes a key role in the regulation of its activity. For this reason, we 
have performed a yeast two-hybrid screening of a brain cDNA library using the ADAM10 
C-terminal tail as bait since this region represents the main biochemical locus for the 
regulation of the trafficking of the enzyme through protein-protein interaction. Among 
the positive clones, we found a protein of particular interest, i.e. CAP2. CAP proteins 
were originally described as Cyclase Associated Protein (hence CAP) from 
Saccharomyces cerevisiae 129. CAPs are evolutionary highly conserved actin-binding 
proteins involved in changes in actin cytoskeleton and in vesicle trafficking/endocytosis, 
linking signalling pathways to elements of the cytoskeleton.  
CAP2 is a multidomain protein expressed only in a limited number of tissues, including 
the brain, suggesting that CAP2 may have unique roles. CAP family has been described 
as an actin-monomer-binding protein that can sequester actin monomers and prevent 
them from polymerization in vitro 129. Recent studies have revealed that CAP proteins 
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promote actin filament dynamics, cooperating with ADF/cofilin both in vitro and in vivo. 
First we confirmed the interaction between ADAM10 and CAP2 using different 
techniques, ranging from coimmunorpecipitation assays to PLA. The two proteins 
interact and this association is specific, since CAP1, the protein homologous to CAP2, 
does not bind ADAM10. Moreover, we identified the domains responsible for the 
association that are the most membrane proximal proline rich domain in ADAM10 tail 
and the N-terminal region of CAP2. 
 Given that, the first aim of our study was to characterize CAP2 in neuronal cells. We 
confirmed the presence of CAP2 in the brain and then we defined the localisation of the 
protein in the neuronal cell, showing that it is present in the excitatory neurons and it is 
localized in the postsynaptic compartment. However, CAP2 is not enriched in the 
postsynaptic density as ADAM10. Moreover, it has been reported in the literature that 
CAP2 can create aggregates through which it can regulate its activity (new). The real 
function of this aggregates and which domains of the protein are involved in the 
oligomerisation are not clear yet. It is known in the literature that Srv2/cyclase-
associated protein (CAP) can create aggregates because of interactions between its C-
terminal region (C) and the N terminal domain (N), but the interaction can occur also 
between C/C and N/N. We demonstrated that the Cysteine-32 is fundamental for the 
self-interaction in the N-terminal region. The biological role of this self-association is not 
clear yet, likely it can affect the localisation of the protein or it can optimize the CAP 
function. To clarify this issue, we analysed the major biological function of CAP2: the 
capability of binding actin and influencing its dynamics. Our results suggested that the 
CAP2 sequesters G-actin monomer in CAP2-clusters detectable in the cytoplasm and 
CAP2 overexpression triggers a shift of the G-actin/F-actin ratio towards G-actin, 
suggesting the induction of cytoskeleton depolymerisation. Interestingly, the rate of 
actin depolymerization depends on the aggregation form of CAP2. Indeed, the G-
actin/F-actin ratio is higher in cells containing one single perinuclear structure compared 
to cells in which CAP2 is organized in cluseters. Even if CAP2  mainly binds G-actin in 
COS7 cells , we demonstrated that in neuronal cells CAP2 can bind F-actin. In neuronal 
cells, we observed that CAP2 overexpression can trigger the actin depolymerisation, 
while CAP2 downregulation reduces G-actin/F-actin ratio. To have more complete view 
of how CAP2 influences the actin dynamics in the spines, we took advantage of the 
FRAP analysis. We silenced CAP2 in hippocampal neuron overexpressing GFP-actin 
that was partially incorporated into the actin filaments 290. The recovery of GFP-actin 
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fluorescence, after the spine bleaching, in CAP2 knockdown neurons was significantly 
increased, compared to control neurons, indicating that there was a significant decrease 
in the stable pool of GFP-actin in the spine. These results suggested that the absence 
of CAP2 increases the treadmilling of actin, leading to a faster rate of actin turnover. 
Thus CAP2 triggers a slower actin dynamic in the dendritic spine and, according to the 
literature, it can coordinate activities in the process of actin treadmilling catalysing 
different steps in actin turnover 137. In support if this hypothesis, it has been recently 
described by Peche and colleagues that CAP2 binds cofilin in neuronal cells, thus 
suggesting that CAP2 takes part to the actin treadmilling cooperating with crucial steps 
of the depolymerisation dynamic. Probably CAP2 interacts with G and F actin mediating 
a complicated exchange of actin monomer, that involves the entire protein structure. 
Therefore, we aimed at identifying the actin binding in CAP2 sequence. In our hands, 
the sequence of CAP2 responsible for the actin binding is composed of the last 22 aa. 
The CAP2 mutant lacking of the last 22 aa was not able to bind actin. However, the loss 
of this domain did not revert the effect of CAP2 on G-actin/F-actin ratio in both COS7 
cells and neuronal cells. 
In light of the above, we assessed the effect of CAP2 on spine morphology: we found 
out that the silencing of the protein determines longer spines, as expected, since CAP2 
downregulation decreases the stable pool of actin in the spines. 
On the other hand, CAP2 overexpression leads to an increase in the width of the spine 
while. the transfection of the mutant lacking of the acting binding domain reverted the 
effect of CAP2 on spines. Since we have demonstrated that this actin binding domain 
does not affect actin dynamics, we wondered that the effect is mediated by ADAM10.  
As previously reported, ADAM10 can modulate the morphology of the spines cleaving 
adhesion molecules, such as N-cadherin. Is CAP2 involved in the trafficking of 
ADAM10? We found out that CAP2 doesn’t modulate the surface expression and the 
endocytosis of ADAM10 but, if we removed the actin binding domain of 22 aa in the C-
terminus, we measured an increase in surface expression of ADAM10 and a decreased 
internalisation index. Therefore, this actin binding site in CAP2 is not involved in the 
regulation of actin dynamics but has a role in the control of ADAM10 membrane levels. 
Therefore, the lack of the last 22aa influences spine shape because it impairs ADAM10 
endocytosis, thus increasing its synaptic levels and thereby its shedding activity towards 
neuronal adhesion molecules.  
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The importance of ADAM10 in spine remodelling is demonstrated by the synaptic 
plasticity-dependent modulation of ADAM10 synaptic localization/activity. Therefore, 
we wondered whether activity-dependent synaptic plasticity modulates also CAP2 
synaptic availability in the dendritic spines. cLTP stimulation caused a significant 
increase in CAP2 dimer levels in TIF. We analysed also the interaction of CAP2 and 
actin and coimmunoprecipitation assays demonstrated a significant decrease in the 
association between CAP2 and actin. Taken together these data demonstrate that LTP 
can modulate CAP2 properties promoting the C32-dependent dimerization in the 
synapses and inducing actin detachment from CAP2. 
The above-described pathways, i.e. ADAM10 cleavage of cell adhesion molecules, 
actin polymerization and spines’ shaping, are required for stabilising synaptic contacts. 
In this framework, we hypothesized that the actin-binding protein CAP2, a newly 
identified partner of ADAM10, can be positioned at the crossroad of such pathways and 
can be implicated in brain pathologies, such as AD, in which there is an impairment of 
the localisation/activity of ADAM10. According to that, microarray analysis of 
hippocampal gene expression of AD patients, reported a downregulation of CAP2 gene. 
Moreover, the CAP2 gene is present at chromosome 6p22.3 in human. An interstitial 
6p22-24 deletion syndrome of the short arm of chromosome 6 was reported where 
patients with this deletion have a variable phenotype including a developmental delay 
168. Since CAP2 could be involved in synaptic failure in both neurodegenerative and 
neurodevelopmental disorders, it represents a potential pharmacological target for 
several diseases. 
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